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CYTOTOXIC EFFECT OF HELICHRYSETIN ON CANCER CELL LINES 
AND ITS MECHANISMS 
 
ABSTRACT 
Helichrysetin is a naturally-occurring compound from the group of chalcones that is 
found in the Chinese ginger, seeds of some Alpinia sp. and flowers of Helichrysum sp.. 
Previous studies have shown that helichrysetin exhibits several biological activities such 
as antiplatelet aggregation, antioxidant, and anti-cancer activity. This compound has 
been found to be effective in the growth inhibition of human breast, liver and cervical 
cancer cell lines but no study on the molecular mechanisms has been performed. Hence, 
this research aims to study the growth inhibitory effect of helichrysetin on four selected 
cancer cell lines and it shows the highest activity on A549 and Ca Ski cell lines. The 
effect of helichrysetin on A549 cell line has been selected for further molecular 
investigation. In this study helichrysetin was found to inhibit A549 cells through the 
induction of apoptosis by triggering mitochondrial-mediated apoptotic pathway. 
Apoptotic cellular and nuclear morphological features were observed in the A549 cells 
after exposure to helichrysetin. Treatment with helichrysetin also resulted in the changes 
in the structure of cell plasma membrane, disruption in the mitochondrial membrane 
potential, cell cycle arrest and damage of DNA mainly internucleosomal DNA 
fragmentation in A549 cells. Proteomic study was performed to further understand the 
signaling cascades in the cells. The proteomic study has revealed the ability of 
helichrysetin to initiate cell death in A549 cells potentially by stimulating oxidative 
stress proven by the stimulation of oxidative stress markers HMOX1 and NRF2. 
Presence of oxidative stress in cells will result in DNA damage. In response to DNA 
damage, DNA damage response and cell cycle arrest are commonly triggered to allow 
for DNA repair. Results from this study showed that helichrysetin causes the 
suppression of proteins related to DNA damage repair such as p-ATM, BRCA1, and 
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FANCD2 and Rb1 hence contributing to the impairment of DNA damage response in 
A549 cells. The inability of the cells to perform DNA repair will trigger the induction of 
apoptosis in the cells. Findings from this study have therefore proven the potential of 
helichrysetin as anti-cancer agent for the treatment of human lung cancer. The discovery 
of its mechanism of action on human lung cancer cells provides a better understanding 
and important information for the development of helichrysetin for future targeted-
cancer therapy.  
 
  
  
v 
 
KESAN SITOTOKSIK HELICHRYSETIN PADA SEL-SEL KANSER DAN 
MEKANISMENYA 
ABSTRAK 
 Helichrysetin adalah kalkon semulajadi yang boleh didapati daripada halia cina, 
biji benih Alpinia sp., dan sesetengah bunga Helichrysum sp.. Hasil kajian saintifik  
menunjukkan helichrysetin mempunyai aktiviti biologi seperti aktiviti antiplatelet, 
antioksidan dan antikanser. Kompaun ini boleh merencat pertumbuhan sel-sel kanser 
payudara, hati, dan serviks. Sehingga kini, tiada kajian mekanisme molekular yang 
pernah dijalankan berkaitan aktiviti antikanser helichrysetin. Objektif penyelidikan ini 
adalah untuk mengkaji aktiviti sitotoksik helichrysetin terhadap empat jenis sel-sel yang 
terpilih. Keputusan kajian menunjukkan helichrysetin adalah efektif dalam perencatan 
pertumbuhan sel-sel kanser serviks, Ca Ski dan sel-sel kanser paru-paru, A549. A549 
dipilih untuk kajian yang lebih lanjut bagi memahami mekanisme molekular sitotoksik 
helichrysetin. Kajian menunjukkan helichrysetin boleh merencat pertumbuhan sel-sel 
A549 melalui induksi apoptosis dengan mengaktifkan laluan intrinsik apoptosis yang 
melibatkan mitokondria di dalam sel. Helichrysetin juga boleh mengakibatkan 
perubahan dari segi ciri-ciri morfologi sel dan nukleus. Selain itu, helichrysetin juga 
menyebabkan perubahan biokimia dalam sel-sel A549 seperti perubahan struktur 
membran plasma, perubahan potensial membran mitokondria, pemberhentian kitaran sel, 
dan kerosakan DNA. Kajian proteomik telah dilakukan untuk memahami perubahan 
mekanisme molekular di dalam sel. Keputusan kajian proteomik menunjukkan 
helichrysetin berpotensi untuk merangsang stres oksidatif di dalam sel dan ini telah 
dibuktikan melalui kehadiran protein-protein yang berkaitan dengan stres oksidatif 
seperti protein HMOX1 dan NRF2. Stres oksidatif boleh menyebabkan kerosakan DNA 
di dalam sel dan ini boleh merangsang mekanisme kerosakan DNA dan pemberhentian 
kitaran sel bagi membolehkan sel membaiki DNA yang rosak. Keputusan menunjukkan 
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helichrysetin telah mengurangkan tahap ekpresi protein yang berkaitan dengan 
mekanisme kerosakan DNA seperti protein p-ATM, BRCA1, FANCD2 dan Rb1. Ini 
boleh menyebabkan kemerosotan respon kepada kerosakan DNA di dalam sel. 
Ketidakupayaan sel-sel untuk membaiki DNA yang rosak akan mencetuskan induksi 
apoptosis dalam sel. Kajian ini telah membuktikan potensi helichrysetin sebagai agen 
anti-kanser untuk rawatan kanser paru-paru. Penemuan mekanisme sitotosiknya 
terhadap sel-sel kanser paru-paru manusia memberikan maklumat yang penting dalam 
penggunaan  helichrysetin sebagai agen terapi kanser  untukrawatan kanser pada masa 
yang akan datang. 
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CHAPTER 1: INTRODUCTION 
1.1 Background of study 
1.1.1 Cancer incidence and death  
Cancer is one of the leading causes of death worldwide with 8.2 million deaths in 2012 
according to World Health Organization (WHO). A project by The International 
Agency for Research on Cancer, GLOBOCAN 2012 showed that there were 14.1 
million new cancer cases while 8.2 million were accounted for cancer deaths with lung 
cancer being the most highly diagnosed cancer followed by breast and colorectal cancer 
worldwide (Ferlay et al., 2015). Lung cancer accounts for 1.8 million new cancer cases 
and 1.6 million cancer deaths globally. The second most common cancer, breast cancer 
followed by colorectal cancer has 1.7 million new cancer cases and 0.52 million cancer 
deaths and 1.4 million new cases and 0.69 million deaths respectively. In Malaysia, 
there are 37,400 people who are newly diagnosed with cancer for both male and female 
in 2012. The number of cancer mortality is 21,700 in 2012 and the 5 most frequently 
diagnosed cancers for both male and female in Malaysia are breast cancer, followed by 
colorectal cancer, lung cancer, cervical cancer and nasopharynx cancer.  
Table 1.1: Number of new cancer cases and cancer deaths worldwide in 2012 for the 
top 3 cancer types(Ferlay et al., 2015). 
Cancer type 
New cancer cases 
(thousand) 
Cancer deaths 
(thousand) 
Lung cancer 1,800 1,600 
Breast cancer 1,700 520 
Colorectal cancer 1,400 690 
Cervical cancer (female) 528 266 
 
 
 
 2 
 
Table 1.2: Malaysia cancer statistics. Number of new cancer cases, deaths and ranking 
of cancers in Malaysia for both male and female (Ferlay et al., 2015). 
MALAYSIA Male Female 
Male & 
Female 
Population (thousands) 14862 14459 29321 
Number of new cancer cases  
(thousands) 
18.1 19.3 37.4 
Number of cancer deaths  
(thousands) 
11.3 10.4 21.7 
5 most common cancers 
  
 1) Lung Breast Breast 
2) Colorectal Cervix uteri Colorectal 
3) Nasopharynx Colorectal Lung 
4) Prostate Lung Cervix uteri 
5) Stomach Ovary Nasopharynx 
    
 
1.1.2 Natural products and its role in cancer 
Natural product has been an important medicinal source for different types of diseases 
and illnesses since ancient times. During the ancient times, people have been using 
natural products as medicines for illnesses such as fever, asthma, constipation, obesity, 
cough, infections and others in the form of traditional medicines, ointments, potions, 
and remedies. 
According to The World Medicine Situation 2011 report, by World Health Organization 
(WHO), 70-95% of populations from developing countries including Asia, Latin 
America, Middle East and Africa are relying on traditional medicines for primary care. 
The development in natural product chemistry has brought to light the importance of 
bioactive metabolites especially secondary metabolites to treat different diseases. This 
has led to the isolation of secondary metabolites from natural resources that become 
prominent in pharmaceuticals.  In 1971, natural products have been used for the first 
time to treatcancer (Hartwell, 1971). Paclitaxel (Weaver, 2014), camptothecin 
derivatives (Venditto et al., 2010), vincristine and vinblastine (Mann, 2002) are 
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clinically approved drugs that have long been used and well-known for the treatment of 
different cancers. Naturally occurring compounds and their derivatives have been 
proven to be able to cause inhibition to cancer cells and have cytotoxic effects to cancer 
cells. The groups of different compounds include the phenolic compounds, flavonoids, 
terpenoids, alkaloids, polysaccharides, lectins and many more.  
Researchers have shown that natural products and the components can result in 
modification to the cancer cells and also initiate cell death in cancer cells. Their actions 
include the modification of gene expression, inducing cell cycle arrest, DNA damage, 
inhibition of cell proliferation, and other characteristics that can cause the induction of 
apoptosis in the treated cancer cells. Hence, natural products are becoming important in 
drug discovery and phytochemicals have become an important component in the search 
for anti-cancer agents. Natural products that are being studied extensively include 
curcumin (Shehzad et al., 2013), resveratrol (Singh et al., 2015), and isothiocyanates 
(Wu et al., 2009) and these bioactive compounds have the potential to become the new 
drug candidates for cancer treatment. 
1.1.3 Discovery of chalcone as potent anti-cancer agent 
Chalcone is biological compound reported to be the precursor of flavonoids and 
isoflavonoids. The structure of chalcone varies in different conjugated forms with two 
aromatic rings joined by a three-carbon unsaturated carbonyl bond. A large number of 
chalcone derivatives can be yielded and these derivatives showed promising biological 
activities like anti-neoplastic, anti-inflammatory, anti-oxidant, anti-hypertensive 
andother biological activities. Hence, these studies have proven that chalcones have 
potential as anti-cancer agents. This group of biological compounds has the ability to 
inhibit the degradation of tumor suppressor protein, pathways related to tumor invasion 
and multi-drug resistance for chemotherapy, to block the process of angiogenesis, and to 
suppress cell proliferation by acting on the cell proliferative signaling pathways.  
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Figure 1.1: Basic chemical structure of chalcone 
Helichrysetin is categorized as chalcone three hydroxyl groups, and one methoxy group. 
Helichrysetin is a naturally occurring chalcone that can be found in rhizomes of 
Boesenbergia pandurata, some plants from seeds of Alpinia sp., and flowers of 
Helichrysum sp. Several studies have proven that this compound exhibits cytotoxic 
activity towards different cancer cell lines. However, no further scientific research has 
been done to investigate the molecular mechanisms related to the inhibitory activity of 
helichrysetin on cancer cells. 
 
Figure 1.2: Chemical structure of helichrysetin 
The purpose of this study is to evaluate the growth inhibitory activity of helichrysetin on 
selected cancer cell lines and normal fibroblast cell line, A549, Ca Ski, HT-29, MCF-7 
and MRC-5 cell lines and to detect apoptotic features and changes to the cell cycle 
progression upon treatment with helichrysetin. In addition, proteomic study is 
performed to investigate the molecular mechanisms involved in the action of 
helichrysetin in causing cancer cell death. 
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1.2 Aim and objectives 
As stated, helichrysetin is a naturally occurring compound with potential to be 
developed as an anti-cancer agent due to its effective growth inhibitory and cytotoxic 
activity on cancer cell lines. This study serves as part of the effort to investigate the 
potential of helichrysetin as a novel anti- cancer drug with minimal undesirable side-
effects, high therapeutic efficiency, and active against some of the untreatable cancer.  
In order to reveal its potential as anti-cancer agent, the following investigations have 
been carried out: 
1) Evaluation of growth inhibitory activity of helichrysetin on four selected human 
cancer cell lines and human normal cell line and observation of the effect of 
helichrysetin on the cellular and nuclear morphology  
2) Detection of the occurrence of apoptosis in cancer cell line upon exposure to 
helichrysetin by detecting its apoptotic features and cell cycle progression. 
3) Investigation of the molecular mechanisms involved in the action of 
helichrysetin on cancer cell lines using bottom up proteomic approach to 
observe the protein changes in the cells. 
1.3 Hypothesis 
The following hypotheses have been considered prior to the beginning of the study: 
1) Helichrysetin can inhibit the growth of the selected human cancer cell line and 
helichrysetin is not active towards human normal cell line. 
2) This compound is able to induce apoptotic cellular and nuclear morphological 
changes in human cancer cells. 
3) Upon exposure to helichrysetin, biochemical apoptotic features will be induced 
in the cancer cells and helichrysetin can induce cell cycle arrest. 
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4) Helichrysetin triggers apoptotic signaling response through the intrinsic or 
extrinsic apoptotic pathways in effect of cellular changes in the cells such as 
DNA damage and cellular stress. 
1.4 Thesis structure 
The thesis was written in 6 chapters. Chapter One presents the general introduction of 
this study including the background, objectives and hypothesis of the study. Chapter 
Two includes literature review on cancer, natural products, chalcone, helichrysetin, 
apoptosis and cell death molecular mechanisms. Chapter Three describes the 
Methodology employed through the whole study. Chapter Four shows all the results and 
findings obtained from this study while Chapter Five contains the discussion and 
conclusion of this study. Chapter 6 concludes the finding and describes the fulfillment 
of the three main objectives of this study. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Cancer 
Cancer can be defined as the result of uncontrolled proliferation of cells in the body. 
The development of cancer occurs through the abnormal tissue growth that no longer 
displays proper cell organization, namely, dysplasia which can later develop into 
neoplasia. As neoplasm emerges, the rate of cell division and cell differentiation 
becomes imbalance. This result in the great number of new cells being produced and 
these cells can further develop into invasive cancer that can migrate and metastasize to 
neighbouring tissues and organs hence disrupting the normal function of the tissue or 
organ. According to Hanahan and Weinberg, there are six biological capabilities that are 
acquired by cells in the process of tumor development. The capabilities include 
sustaining proliferative signaling, evading growth suppressors, cell death resistance, 
activation of replicative immortality, angiogenesis, and activating metastasis and 
invasion (Hanahan et al., 2011). 
 
Figure 2.1: The development of normal tissue to invasive cancer. Cancer progression 
occurs at different points and gene mutations contribute to the progression from normal 
tissue to dysplasia, carcinoma in situ and to invasive cancer. (Source: Umar et al.,2012) 
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Carcinogenesis or cancer development can be divided into different stages, tumor 
initiation, tumor promotion, and tumor progression. Genetic mutation has been widely 
known as the early event in carcinogenesis; however, it has been found that epigenetics 
also contributes to the development of cancer. Chemical carcinogen can trigger genetic 
error by changing the structure of DNA which will be inherited through DNA synthesis 
and replication and this is done by the formation of adduct between the carcinogen with 
DNA (Yuspa et al., 1988). Initiated cells will undergo clonal expansion in the tumor 
promotion stage.  
Tumor promoters are able to cause biological effects without affecting the metabolic 
process and they are commonly non-mutagen or carcinogen. Tumor promoters are able 
to cause tumor formation by increasing the number of tumors in a tissue in a short 
latency period (Verma et al., 1980). In the tumor progression stage, malignant 
phenotype starts to be expressed and malignant cells will acquire aggressive 
characteristics with the tendency for genomic instability and uncontrolled growth 
(Lengauer et al., 1998). 
Cancer can be distinguished as either benign or malignant tumors. The growth of benign 
tumor is restricted to its local area while malignant tumor invades the neighbouring 
tissue and spread throughout the body via the circulatory system. Cancers are 
commonly categorized in to three main groups namely carcinoma, sarcoma and 
lymphoma. Carcinoma, sarcoma and lymphoma are of epithelial, connective tissues and 
blood or lymphatic origins respectively.   
2.2 Natural products and cancer 
Natural products play a big role in the effort of discovery and development of drugs for 
different diseases. People from different cultures have used a variety of natural products 
as traditional medicine and some proven to have potent anticancer effects. Prominent 
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naturally-derived anticancer drugs include campthothecin, vincristine, vinblastine, and 
paclitaxel (Bhanot et al., 2011).  
The vinca alkaloids, vincristine and vinblastine are the first agents that participitated in 
the clinical use for the treatment of cancer including lung cancer, leukemia, breast 
cancer, and Karposi’s sarcoma and these alkaloids are derived from the Madagascar 
periwinkle (Chen et al., 2012; Devita et al., 1970).  
While paclitaxel that comes from the bark of Pacific yew tree is another proven success 
of the usage of natural products as anti-cancer agent. Paclitaxel is effective towards 
breast cancer, non-small and small cell lung cancer, and ovarian cancer. It targets on the 
tubulin of cells and stabilizes the structure of microtubule that leads to the blockage in 
the progression of mitosis (Demidenko et al., 2008). Prolonged mitosis will result in the 
occurrence of apoptosis and reversion of the cell cycle.  
Camptothecin is extracted from the plant Camptotheca acuminate which exhibits anti-
cancer activity towards different types of cancer cells and it acts by inhibiting DNA 
topoisomerase I causing death to cancer cells (Gaur et al., 2014). However, due to its 
poor solubility and stability, camptothecin derivatives have been developed such as 
irinotecan and topotecan. These two compounds have been clinically approved for use 
on metastatic colorectal cancer, ovarian cancer, cervical cancer and small-cell lung 
cancer respectively (Venditto et al., 2010). Studies are also being conducted to use 
camptothecin derivatives in late-stage cancer therapy and also in combination with other 
drugs (Harasym et al., 2007). 
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2.3 Chalcone 
 
Figure 2.2: Chemical structure of chalcone 
Chalcone, trans-1, 3-diaryl-2-propen-1-ones, consists of two aromatic rings with a 
diverse array of substituents. It belongs to the flavonoid family and is the precursors of 
open chain flavonoids and isoflavonoids that can be found abundantly in plants 
(Rahman, 2011). The two aromatic rings in chalcones are connected by an electrophilic 
three carbon α, β-unsaturated carbonyl system (Awasthi et al., 2009). It has developed a 
vast interest for medicinal chemist because it has displayed a wide spectrum of 
pharmacological effect such as anticancer, antioxidant (Vogel et al., 2008), 
antimicrobial, antifungal (Bag et al., 2009), anti-inflammatory (Hamdi et al., 2011), 
antibacterial activities (Yadav et al., 2011).  
Chalcones have been found to inhibit multi-drug resistance (MDR) channels part of 
being chemosensitizers by improving the absorption of cancer chemotherapeutic drugs 
that are poorly absorbed in the intestine (Vasiliou et al., 2009). Chalcones also act as 
inhibitors for the degradation of tumor suppressor proteins (Issaenko et al., 2012), p53 
which prevents cancer by regulating cell cycle, mediates apoptosis, DNA repair, 
genome stability and inhibition of angiogenesis. It’s been reported that chalcone 
derivaties inhibited the JAK/STAT signaling pathway which when activated can caused 
abnormal growth of malignant cancer and neoplastic transformation (Pinz et al., 2014). 
Zhu et al. had demonstrated the ability of 2,4-dihydroxy-6-methoxy-3,5-
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dimethylchalcone to inhibit the phosphorylation of KDR tyrosine kinase, a vascular 
endothelial growth receptor (VEGF) resulting in the inhibition of the growth of human 
vascular endothelial HDMEC cells consequently blocking the process of angiogenesis 
(Zhu et al., 2005). Cell proliferation can be suppressed by the action of chalcones due to 
its inhibition on Cathepsin-K (Ramalho et al., 2013) that contributes to tumor invasion, 
tubulin assembly in cell cycle, mTOR signaling pathway (Sun et al., 2010), NF-KB 
inhibition (Orlikova et al., 2012), and also its cytotoxic activity (Nakhjavani et al., 2014) 
2.3.1 Helichrysetin 
Helichrysetin,1-(2,4-dihydroxy-6-methoxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-
one was isolated as orange-yellow crystal with the melting point of 248 ºC and 
molecular weight of 286 g/mol. It was isolated from the flowers of Helichrysum 
odoratissimum (Van Puyvelde et al., 1989), Helichrysum foetidum (Zanetsie Kakam et 
al., 2011), rhizomes of Boesenbergia pandurata (Tewtrakul et al., 2009), seeds of 
Alpinia blepharocalyx.  
Synthesis of helichrysetin was also done by Puyvelde et al. Helichrysetin was 
synthesized by the condensation of 1,3-dihydroxy-5-methoxy-benzene with MeCN to 
produce ketimine hydrochloride. It was the hydrolysed to yield 2,4-dihydroxy-6-
methoxyacetophenone. Finally, it was condensed with aldehyde in 60% aqueous KOH 
containing some ethanol to give helichrysetin (Van Puyvelde et al., 1989). 
 
Figure 2.3: Chemical structure of helichrysetin 
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Helichrysetin isolated from Alpinia blepharocalyx have been shown to have strong 
platelet aggregation inhibition (Doug et al., 1998). Helichrysetin had shown a high 
cytotoxic effect on HeLa cell line in the MTT cell proliferation assay with the IC50 
value of 5.2 ± 0.8 µM (Vogel et al., 2008).  
This natural compound isolated from the seeds of Alpinia katsumadai showed inhibition 
against human liver cancer cell line HEPG2 and human breast cancer cell lines MCF-7 
and MDA-MB-435 with IC50 values of 14.64 µg/ml, 24.22 µg/ml and 1.83 µg/ml 
respectively (Hua et al., 2008).  
It was reported that substitution of hydroxyl group, electron donating group at the ortho 
and para position of benzene can enhance tumour reducing activity (Anto et al., 1995). 
Chalcone that was found to have high antitumour activity also possess the antioxidant 
activity. Hence, the antioxidant activity of helichrysetin has also been investigated with 
the remarkable activity of 4.4 ± 0.6 Trolox equivalents in ORAC-fluorescein assay.  
2.4 Development of cancer and cell death 
Clinicians and researchers have been striving to look for novel targets for cancer to 
improving existing cancer therapies. The development of cancer or tumorigenesis has 
been highly related to the changes in genetic information of cells and biological 
processes play an essential role in sustaining tumorigenesis. Review by Hanahan and 
Weinberg discussed the biological processes involved in tumorigenesis and the 
resistance of cell death is proposed as an important mechanism that sustain 
tumorigenesis and malignant transformation (Hanahan et al., 2011).  
Hence, the deregulation of apoptosis has come into the light as one of the hallmarks of 
cancer. This deregulation is facilitated by the occurrence of mutations in oncogenes and 
tumor suppressors. The tumor suppressor gene TP53 is highly mutated in human cancer 
which has been linked to apoptosis (Amundson et al., 1998). Even though there is a 
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huge number of biological processes and therapeutics agents known and available, most 
of these agents are still depending on the induction of apoptosis to kill cancer cells. 
Therefore, it is important to discover potential cancer drugs that causes cancer cell death 
through apoptosis. 
Other components that are frequently deactivated in human cancer are MDM2, ARF, 
RB1 which are responsible for regulation of DNA damage checkpoint pathways (Møller 
et al., 1999). Ras gene which is involved in kinase signaling pathways for cell growth 
and differentiation is also an oncogene that is commonly mutated in cancer such as 
colon, lung, pancreas, breast, liver and ovarian cancer (Schubbert et al., 2007). Hence, 
this protein encoded by Ras gene and those important for the formation of cancer cells 
become important drug target over the years.  
 
Figure 2.4: The hallmark of cancer displaying the characteristics of cancer cells for 
development of cancer and drugs that specifically interfere with each of the ability of 
cancer for tumor growth and progression that have been clinically-approved or in 
clinical trials. (Source: Hanahan and Weinberg,2011) 
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2.4.1 Cell viability assays 
The commonly used method to screen molecules for its effect on cell proliferation is by 
using cell-based assays. The amount of live cells that remain at the end of the 
experiment will be measured. Cell-based assays can help to measure specific events in 
the cells upon exposure to treatments, such as cell organelle activities, cellular 
components trafficking, and different types of signal transductions events (Quent et al., 
2010). Cell-based assays can be performed using different methods such as multi-well 
formats, flow cytometry, and high content imaging (Kepp et al., 2011).  
Cell viability can be measured using different indicators such as fluorescence, 
absorbance, and luminescence detection methods and this is often measured by 
quantifying parameters such as membrane integrity, esterase activity, ATP levels, or 
simply by counting the cell nucleus (Gilbert et al., 2011).  The most commonly used cell 
viability assays forin vitro toxicology studies are MTT assay, neutral red assay, LDH 
leakage, and protein assays upon exposure to potential toxic substances (Fotakis et al., 
2006). 
2.4.2 Morphological characteristics of cell death 
Cell death in animal cells is discriminated into three main forms, apoptosis, necrosis and 
autophagic cell death (Kroemer et al., 2005). Morphological features of apoptosis are 
pyknosis, chromatin condensation, karyorhexis, plasma membrane blebbing and cell 
rounding (Kerr et al., 1972). The initiation of apoptosis is induced by different types of 
stimuli and its occurrence requires a series of signal transduction and downstream 
process (Ziegler et al., 2004).  
In autophagic cell death, there is an increase autophagosomes which will later fuse with 
lysosomes for degradation process (Levine et al., 2004). Autophagy is normally seen as 
a pro-survival mechanism but it is also involved in promoting cell death.  
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Necrosis is a mechanism of cell death that is often stress-induced. In the past, necrosis 
has been seen as a process without proper mechanisms, however in recent years, 
researchers have shown that the process of necrosis will involve a series of mechanisms 
too. Necrosis is characterized by swollen organelles in the cells, rupture of plasma 
membrane, increase in cell volume, and exposure of intracellular components into the 
outer environment (Denecker et al., 2001). 
 
Figure 2.5: The morphological features of three main cell death processes, apoptosis, 
autophagy and necrosis. (Tan et al., 2014) 
2.4.3 Apoptosis 
Apoptosis is described as programmed cell death responsible for the tissue homeostasis 
in multicellular organisms by maintaining the balance between cell death and cell 
proliferation. Apoptosis can occur under normal physiological or pathological settings. 
The failure to regulate the mechanisms of cell suicide will result in the development of 
diseases (Fadeel et al., 2005).  
In some pathological conditions when there is too much apoptosis, it will initiate the 
development of degenerative diseases. In the case of cancer, there is too little apoptosis 
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which results in the uncontrolled growth of malignant cells. Since the deregulation of 
apoptosis is one of the main reasons for the development of diseases including cancer 
when cells are resistant to programmed cell death, hence, a better understanding of this 
condition is important to help develop possible therapeutic strategies for the treatment 
of cancer. 
 
Figure 2.6: Role of apoptosis in human disease. Apoptosis is responsible for tissue 
homeostasis and its disruption will contribute to the pathogenesis of some human 
diseases. (Fadeel and Orrenius, 2005) 
2.4.4 Features of apoptosis 
Morphological characteristics of apoptosis in the nucleus are fragmentation of nucleus, 
and chromatin condensation together with the changes in the cellular morphology by the 
rounding of the cells, and reduction in the cell volume (Kroemer et al., 2005). Upon 
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chromatin condensation that occurs at the periphery of nuclear membrane, chromatin 
will continue to condense until it breaks up in the cell while the membrane remains 
intact. This phenomenon is termed karyorhexis (Majno et al., 1995).  
In the later stage of apoptosis, extensive membrane blebbing leads to separation of cell 
content through the formation of apoptotic bodies. This stage involved the disruption in 
the plasma membrane integrity and also structural modification of organelles in the 
cytoplasm. Then, the apoptotic bodies from the dead cells will be engulfed through 
phagocytosis (Krysko et al., 2006). In the case where apoptotic cells are not engulfed by 
phagocytosis, they turn to secondary necrotic cells (Silva, 2010). 
The occurrence of apoptosis also involved a few types of biochemical changes. As 
discussed earlier, in late apoptosis, disruption of plasma membrane integrity occurs and 
in order for this to happen in the earlier stage apoptosis, phosphatidylserine is flipped to 
the outer layer of plasma membrane. Following this, dead cells will be recognized by 
macrophages for degradation by phagocytosis (Kumar et al., 2010). Upon membrane 
blebbing and chromatin condensation, chromosomal DNA will be cleaved sequentially 
to oligosomal DNA fragments with the size of 50 to 300 kilobases  pair and then to 
multiples of 180 to 200 base pairs (Vaux et al., 2003).  
The breaking down of apoptotic protein is also a specific feature of apoptosis. A group 
of enzymes under the family of cysteine proteases named caspases will be activated. 
Caspases are enzymes that cleave aspartic acid residues by cysteine in its active site in 
many important cellular proteins involved in the process of apoptosis which include the 
proteins that support the structure of nucleus and cell cytoskeleton (Fan et al., 2005). 
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Figure 2.7: Features of apoptosis. Apoptosis causes changes to morphological and 
biochemical characteristics to cells. 
Techniques performed to study the features of apoptosis should allow quantification, 
observe the qualitative differences in different experimental conditions, distinguish 
different stages of apoptosis, and revelation of molecular changes in different conditions 
(Archana et al., 2013). Changes in the morphology of the cells can be identified by light 
microscopy specifically during the early apoptosis when the cells start to shrink and 
pyknosis occur (Ziegler et al., 2004). A better view of the subcellular changes can be 
defined by applying electron microscopy which shows distinct changes like chromatin 
condensation and nuclear material aggregating under the nuclear membrane (Louagie et 
al., 1998), extensive membrane blebbing and formation of apoptotic bodies (Lawen, 
2003).  
One of the features of apoptosis is the fragmentation of DNA in the cells and this can be 
observed using the gel electrophoresis. Gel electrophoresis is a reliable technique to 
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visualize the high molecular weight DNA fragments approximately about 300kb 
(Higuchi, 2004) (Singh, 2000).  
 
Figure 2.8: Structure of high molecular weight DNA fragment and formation of low 
molecular weight DNA fragment. DNA fragments base pairs detected using gel 
electrophoresis to visualize DNA ladder (Scarabelli et al., 2006).  
For accurate quantification of apoptotic cells, components in the cells can be stained 
with fluorochromes to detect apoptotic features using flow cytometry. DNA 
fragmentation in the cells can be quantified using flow cytometry detection by terminal 
deoxy transferase transferase-mediated dUTP nick end labelling (TUNEL), propidium 
iodide (PI), 4ˊ, 6-diamino-2-phenylindole (DAPI). To detect the loss of membrane 
integrity, cells can be stained with annexin-V fluorochrome to quantify number of cells 
that have undergone phosphatidylserine externalization that occurs in the calcium 
dependent manner (Vermes et al., 1995).  
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Figure 2.9: Externalization of phosphatidylserine (PS) to the extracellular space of the 
cells during the occurrence of apoptosis (Sogbein et al., 2014).  
2.4.5 Mechanisms of apoptosis 
It is important to understand the mechanisms underlying the process the apoptosis in 
order to know the pathological conditions of deregulated apoptosis in the cells. This will 
provide insights in the development of drugs which will target particular pathways or 
genes related to apoptosis for cancer therapy. 
Apoptosis consists of upstream regulators and downstream effector components. The 
initiation pathways that are frequently described are the intrinsic and extrinsic apoptotic 
pathways that are triggered in mitochondrial and by death receptors respectively (Fulda, 
2010). Apoptosis also can be triggered by intrinsic endoplasmic reticulum pathway, a 
pathway that is not commonly known (Breckenridge et al., 2003). 
Intrinsic mitochondrial pathway is triggered by the internal stimuli for example 
oxidative stress, irreparable genetic damage, hypoxia and high concentrations of Ca
2+
 in 
the cytosol (Karp et al., 2008). Upon stimulation of this pathway, the permeability of 
mitochondria will be increased and pro-apoptotic molecules will be released from the 
mitochondria to the cytoplasm (Danial et al., 2004). Bcl-2 family proteins are important 
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proteins that regulate the intrinsic apoptotic pathway and the proteins are separated into 
pro-apoptotic and anti-apoptotic Bcl-2 family proteins (Siddiqui et al., 2015). The 
balance of these two groups of protein is important to determine the initiation of 
apoptosis in the cells. Anti-apoptotic proteins consist of four Bcl-2 homology (BH) 
domains that serve as protection to the cell from apoptotic stimuli. Anti-apoptotic 
proteins include Bcl-2, Bcl-xL, Mcl-1, Bcl-w and others, while the BH-3 only proteins 
include Bid, Bim, Bad, Puma, Noxa and others that are restricted to BH-3 domain only. 
Pro-apoptotic proteins are activated upon stimulation by cellular stress such as DNA 
damage, ER stress and growth factor depletion, and they contain all four BH domains 
and these proteins are Bax, Bak and Bok/Mtd proteins (Dewson et al., 2010). 
The initiation of intrinsic pathway will induce other apoptotic factors such as apoptosis 
inducing factor (AIF), direct IAP Binding protein with Low pI (DIABLO), and second 
mitochondria-derived activator of caspase (Smac) (Kroemer et al., 2007). These 
apoptotic factors are responsible to bind to the inhibitor of apoptotic proteins which 
block the interference of IAPs to caspases (LaCasse et al., 2008). 
The extrinsic apoptotic pathway is triggered by the binding of the death ligands to the 
death receptor. The most characterized death receptors are CD95 (Fas) receptor, TNF 
receptor 1 (TNFR1), TNF-related apoptosis-inducing ligand-receptor 1 (TRAIL-R1) 
and TRAIL-R2 (Walczak et al., 2000). Death receptors consist of death domains that 
transmit death signals from the surface of cell membrane into the cell. Death domains 
will be recruited to the death receptor and this will cause the formation of death-
inducing signaling complex (DISC) which will activate caspase 8 and result in the 
activation of downstream apoptotic pathways (Ganten et al., 2004). 
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Figure 2.10: Intrinsic and extrinsic apoptosis cascades. Intrinsic pathway triggered by 
cellular stress while extrinsic pathway triggered by death receptor that cause apoptotic 
cell death. (Chipuk & Green, 2006) 
In the intrinsic endoplasmic reticulum pathway, ER stress is coupled with the activation 
of caspase-12 and caspase 12 is localized at the cytosolic side of ER to prepare for the 
respond to ER stress and a signaling molecule (Nakagawa et al., 2000). When ER is 
exhausted by cellular stresses such as hypoxia, oxidative stress or glucose depletion, 
there will be reduction of protein synthesis and unfolding of proteins which will cause 
the dissociation of TNF receptor associated factor 2 (TRAF2) from procaspase 12 
subsequently activating the caspase 12 (O'Brien et al., 2008). 
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Figure 2.11: Endoplasmic reticulum (ER) stress induced apoptosis. ER stress-induced 
apoptosis is triggered by three main pathways, the proapoptotic pathway of 
CHOP/GADD153 transcription factor, IRE1 mediated-activation of apoptosis and 
activation of ER localized cysteine proteases. (van der Kallen et al., 2009) 
In relation to this, p53, a well-known tumor suppressor protein plays a role as the 
central control governing the fate of the cells to undergo proliferation or apoptotis. 
Despite p53 being a tumor suppressor, p53 is often mutated in the cancer cells which 
contribute to the oncogenic property of cancer (Muller et al., 2013). Upon stimulation of 
p53 by intracellular cell stress and abnormality sensors such as excessive genome 
destruction, or growth-promoting signals, nucleotide pools and oxygenation being at 
lower than optimal level, p53 will stop the cell cycle progression and trigger apoptosis 
(Hanahan et al., 2011). More than half of the human cancers are linked to the mutation 
in the p53 protein and this protein is involved in many cellular processes such as 
apoptosis, cell cycle, cell differentiation, cellular senescence and others (Oren et al., 
1999). One of the studies has found that when p53 mutant was silenced, it reduced the 
growth of cancer cells and this is found to be due to the occurrence of apoptosis in the 
cells (Vikhanskaya et al., 2007). The importance of understanding the molecular 
mechanisms has led researchers to use Western blotting to monitor the changes in the 
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molecular mechanisms of apoptosis in certain experimental conditions (Chandra et al., 
2009). 
2.5 Mitochondria as a target for cancer therapy 
Mitochondria play an important role in cellular processes. Its actions involve the 
regulation of ATP production via oxidative phosphorylation in the inner mitochondrial 
membrane (Leist et al., 1997). The disruption in mitochondrial function can result in the 
development of diseases. Mitochondria participate in the mechanisms cell death because 
they play important role in cellular apoptotic responses.  
Studies have shown the efficacy of compounds that inhibit mitochondrial function such 
as tigecycline that significantly inhibits mitochondrial respiration, disrupts 
mitochondrial membrane potential and increases reactive oxygen species in non-small 
cell lung cancer (Jia et al., 2016). Gamitrinib, a small molecule Hsp90 inhibitor has 
been proven to induce acute mitochondrial dysfunction in advanced prostate cancer 
cells with loss of membrane potential, cytochrome c release, and activation of caspase 
activity (Kang et al., 2010).   
2.5.1 Mitochondria and apoptosis 
Mitochondrial outer membrane permeabilization is an indicator of an irreversible event 
where cells commit suicide. During the onset of apoptosis, there is normally a 
dissipation of the mitochondrial inner transmembrane potential (Green et al., 2004). 
Commonly, upon mitochondrial outer membrane permeabilization, cytochrome c is 
released into the cytosol of the cells. It’s been found that in apoptotic cells, after the 
release of cytochrome c and the activation of caspases will feed back to the 
permeabilized mitochondria to destroy the mitochondrial transmembrane potential and 
this will subsequently result in the generation of ROS by the action of caspases in 
electron transport chain (Ricci et al., 2003).  
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Since the collapse of mitochondrial membrane is highly related to its membrane 
potential, apoptosis in the cells can be quantified using flow cytometry method using a 
cyanine dye JC-1 (5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimi-dazolylcarbocyanine 
iodide). This dye can be used to detect the polarization and depolarization of the 
mitochondrial membrane as an indication of apoptosis (Perelman et al., 2012). 
 
Figure 2.12: Models displaying the permeabilization of mitochondrial outer membrane. 
a) BH3-only proteins activate Bax proteins that leads to the formation of pores in the 
mitochondrial outer membrane. b) Death signals activate the opening of the 
permeability transition pore (PTP) leading to the disruption of mitochondrial membrane 
potential. (Martinou & Green, 2001)  
Cytochrome c binds with adaptor molecule APAF-1 in the cytosol leading to an 
extensive conformational change that causes it to form a heptameric structure which we 
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called it apoptosome. Subsequently, apoptosome formed will recruit pro-caspase 9 and 
activate it which will then cleave and activate two executioner caspases, caspase 3 and 
caspase 7 (Taylor et al., 2008). Hundreds different substrates will be cleaved by caspase 
3 and 7 which will effectively kill the cells within a few minutes. 
2.5.2 Role of Bcl-2 proteins in mitochondrial-related apoptosis 
Mitochondrial membrane potential change is largely regulated by the members of Bcl-2 
protein family. These proteins can be separated into three divisions, pro-apoptotic 
effector proteins, pro-apoptotic BH3-only proteins, and anti-apoptotic proteins. The 
proteins that belong to these divisions are as followed: 
Table 2.1: Bcl-2 family protein names categorized into its sub-divisions (Hardwick & 
Soane, 2013). 
Bcl-2 protein family Protein names 
Pro-apoptotic effector proteins Bax, Bak 
Pro-apoptotic BH3-only proteins Bid, Bim, Puma, Noxa, Hrk, Bik, Bmf, Bad 
Anti-apoptotic Bcl-2 proteins Bcl-2, Bcl-Xl, Mcl-1, A1, Bcl-B, Bcl-W 
 
As an effect of apoptotic stress or cell damage, Bcl-2 family proteins will be activated. 
These proteins cause the activation of the pro-apoptotic proteins, Bax and Bak in 
mitochondria. Bax and Bak are gathered to form oligomers which contribute to the 
formation of pores in the outer membrane of mitochondria, subsequently the release of 
cytochrome c and activation of caspases for apoptosis (Certo et al., 2006).  
The mechanism of mitochondrial outer membrane permeabilization ultimately 
represents an irreversible action. BH3-only proteins consist of activators or sensitizers 
that neutralize the effect of anti-apoptotic Bcl-2 proteins, hence, most of the drugs can 
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act as BH3-only proteins finally activating apoptosis in the targeted cells(Lopez et al., 
2015). 
 
Figure 2.13: Execution of mitochondrial-mediated apoptosis by the involvement of 
BH3-only proteins to activate apoptosis through the occurrence of mitochondrial outer 
membrane permeabilization (Lopez & Tait, 2015). 
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2.6 Cell cycle regulation 
 
Figure 2.14: The regulation of mammalian cell cycle by cyclin-CDK complexes. Cell 
cycle is made up of the S phase (DNA synthesis), M phase (mitotic phase) that are 
separated by G1 and G2 phase of the cell cycle. (Suryadinata et al.,2010) 
Regulation of cell cycle is important in maintaining the development of multicellular 
organisms. The deregulation of cell cycle can cause the rise of different diseases and 
this includes the development of cancer.  
Cell cycle mainly consists of four phases G1, S, G2 and M phase and its progression is 
highly driven by cyclin-dependent kinases (CDK) in combination with cyclins. Cell 
cycle progression through each phase of the cell cycle is monitored by checkpoints 
which will ensure the accuracy of the cell cycle events (Hartwell et al., 1989).  
When problems occurred during cell cycle, cell cycle checkpoints will be activated to 
induce cell cycle arrest and at this point, the fate of the cells will be determined by 
undergoing DNA repair or the cells will undergo cell death (Viallard et al., 2001). When 
the cell cycle checkpoints are disrupted, it can result in the development of cancer. 
Uncontrolled proliferation of cells is the main player in the development of cancer; 
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hence, it has been proposed and tested by researchers to use anti-cancer agents to target 
on cell cycle checkpoints. 
The activation of the mitogenic signaling cascade will allow cells entry into the 
regulated steps in cell cycle. In the S phase of cell cycle, genome duplication occurs at 
which there is synthesis of DNA in the cells. In G1 phase, cells will commit into 
entering the new cell cycle (Senderowicz, 2004). This stage is controlled by the G1-S 
transition at which cyclin-dependent kinases (CDKs) complexes will be activated to 
allow entry into S phase. The regulation at this point is controlled by the G1/S cell cycle 
checkpoint. G2 checkpoint will help prevent cells with damaged DNA to enter the M 
phase for cell division (Paulovich et al., 1997). At this point, damaged cells will stop 
proliferating and some will undergo DNA repair.  
2.6.1 Cyclin-dependent kinases and cyclins in cell cycle regulation 
Cyclin-dependent kinases (CDK) are heterodimeric serine/threonine protein kinases that 
are made up of two subunits known as CDK which has catalytic function and cyclin 
which has regulatory function (Malumbres et al., 2007). CDKs play very important role 
in the mechanisms of cell cycle progression. To perform their function in cell 
proliferation, CDKs need to form complexes with cyclins. A total of twenty CDKs have 
been found in mammals that play different roles in cell cycle events or transcriptional 
regulation while some CDKs functions remain unknown (Malumbres et al., 2009). 
CDKs, cyclins and CDK inhibitors are important to maintain cellular homeostasis and 
the dysregulation of these substrates will cause the development of cancer (Maddika et 
al., 2007). CDKs are highly altered in tumors; therefore, many studies have been going 
into searching for therapeutics strategy against cancer by targeting CDKs. Cells 
proliferate uncontrollably when CDKs become overactive and cause the tumor 
suppressor genes to become dysfunctional.  
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CDK4 and CDK6 act as the interphase cyclin dependent kinases that regulate cell cycle 
progression through G1 phase. These two CDKs are activated by the D-type cyclins to 
form complexes and cyclin Ds are highly produced upon activation by mitogenic 
signalling (Zhang et al., 2002). Then, phosphorylation will occur which will partially 
inactivate retinoblastoma (Rb) proteins that are responsible to suppress transcription of 
genes related to DNA replication (Sheppard et al., 2013).  
Following the phosphorylation of Rb protein, E-type cyclins bind and activate CDK2 
then activating E2F that allow the entry into S phase of cell cycle (Ortega et al., 2002) 
then CDK2 combines with cyclin A to allow the transition from S phase to G2 phase. 
Towards the end of S phase, CDK1 form complexes with cyclin B to initiate mitosis (M) 
in the cells at the same time phosphorylating a large number of regulatory and structural 
proteins required for the process of mitosis (Castedo et al., 2002). 
2.6.2 Cell cycle and cancer therapy 
Given the importance of CDKs and cyclins in the regulation of cell cycle, cancer has 
also been deduced as a disease of cell cycle whencancer cells proliferate uncontrollably 
without proper regulation. In addition, alteration of cell cycle machinery is highly linked 
to the development of cancer and most molecules related to cell proliferation have been 
associated with malignant transformation.  
There are studies that look into the inhibition of cell cycle proteins that work together 
with CDKs in different phases of cell cycle such as targeting the CDC7 kinase which is 
involved in the regulation of S-phase progression and this has become a major target of 
drug development by major pharmaceuticals company such as Pfizer, Roche, Novartis, 
Nerviano Medical Sciences, and Bristol Myers Squibb. The inhibitors displayed 
antitumor activity in pre-clinical studies hence these inhibitors such as NMS-1116354 
by Nerviano and BMS-863233 by Bristol Myers Squibb have entered the phase I-II 
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clinical trials (Swords et al., 2010). There are also a number of drugs frequently used to 
target CDK activities in chemotherapy. These drugs commonly affect the cell cycle 
machinery and transcriptional CDKs to cause cell cycle arrest eventually cell death 
(Shapiro, 2006). 
Cell cycle checkpoints are the supervisors and signalling pathways that are responsible 
for the coordination of DNA repair with cell cycle transitions. Upon the occurrence of 
DNA damage, checkpoint proteins will be recruited to the DNA which will activate 
checkpoint response (Bartek et al., 2007). Defects in DNA damage checkpoints will 
result in over activation of CDK, progression of cell cycle with the damaged DNA, 
which will finally developed into cancer. Cells with genome instability and presence of 
mutants will cause the cells to acquire malignant characteristics. CHK2 is one of the 
tumor suppressors that are commonly altered for example in colon and breast cancer 
and this caused the high expression of E2F1 transcription factor (Stawinska et al., 2008).  
Studies have shown that a natural compound β-lapachone and its derivatives can elevate 
the formation of reactive oxygen species (ROS) and DNA damage in cancer cells that 
causes cancer cell death (Rios-Luci et al., 2012) and also stabilization of E2F1 (Li et al., 
2003). Hence, targeting CDKs is a therapeutic approach with good potential for the 
treatment of cancer.  
2.7 Oxidative stress and cancer cell death 
DNA and cells are persistently exposed to attacks of oxidative stress and free radicals. 
Oxidative stress can come from different sources, exogenous and endogenous. 
Exogenous oxidative stress comes from the environment such as radiations and 
oxidizing chemicals while endogenous stress also known as intracellular oxidative stress 
produced by cellular signalling or in metabolic processes (Sedelnikova et al., 2010). 
Endogenous oxidative stress can result in a high level of DNA lesions in the cells and 
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this damage is primarily caused by the induction of reactive oxygen species (ROS) such 
as superoxide anion, hydrogen peroxide, singlet oxygen and hydroxyl radical and 
peroxyl radical while reactive nitrogen species (RNS) consists of nitric oxide, 
peroxynitrite and nitrogen dioxide.  
In normal cells, there exists an equilibrium between antioxidant and pro-oxidant 
regulated by ROS-metabolizing enzymes. However, when there is an imbalance or 
disturbance in this equilibrium, oxidative stress will happen that brings impact to some 
biological and pathological processes (Trachootham et al., 2008). Disturbance in 
oxidative balance is usually overcome by cell’s own mechanism but prolonged 
imbalance of oxidative condition will result in cell death (Genestra, 2007). 
Intracellular ROS are commonly produced by mitochondria as a byproduct of electron 
transport system. Even though ROS production is acceptable in the cellular metabolism 
aspect, when it reacts with the other components such as proteins, DNA, carbohydrate, 
lipids and other cellular components, it can damage the cells. Cells usually adapt to 
oxidative stress with the help of two proteins Kelch like-ECH associated protein 1 
(Keap1) and transcription factor NFEL2L2 (Nrf2). Nrf2 levels are maintained in the low 
basal levels in the absence of oxidative stress (Zhang et al., 2003). When oxidative 
stress occurs, Keap1 is not able to target Nrf2 which will increase the level of Nrf2 
proteins causing the transcription of antioxidant response gene such as NAD(P)H 
dehydrogenase, quinone 1 (NQO1), catalase (CAT) and heme oxygenase 1 (HMOX1) 
(Malhotra et al., 2010). ROS can induce several types of DNA damage which include, 
single strand DNA breaks (SSB), double strand DNA breaks (DSB), oxidized purines 
and pyrimidines, and apurinic/apyrimidinic DNA sites (Kryston et al., 2011).  
DNA damage caused by free radical can have deleterious effect on the biology of the 
cells which will lead to formation of cancer. However, high intracellular level ROS in 
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the cells can also cause the cell cycle arrest as a result of DNA damage and this will 
subsequently trigger apoptosis. Oxidative stress can cause the release of cytochrome c 
from the mitochondria which then lead to the occurrence of apoptosis (Ueda et al., 
2002).   
Free radicals can trigger a series of biological events and one of the events is the ROS-
mediated JNK activation of cell death that includes apoptosis and necrosis (Shen et al., 
2006). This phenomenon provides opportunity for the exploitation of cellular 
mechanisms and to be one of the cancer therapeutics method and some studies have 
shown that there are natural products that can induce the production of ROS in cancer 
and subsequently caused DNA lesions and death to the cancer cells (Ahsan et al., 1998).  
Example of a naturally occurring compound, melatonin which is found in plants, fungi, 
bacteria and animals is a prominent antioxidant but studies have found that melatonin 
have pro-oxidant ability. It has been shown that melatonin can stimulate the production 
of ROS which later melatonin promoted Fas-induced apoptosis (Wölfler et al., 2001). 
This compound has also been found to cause cytotoxicity in human leukemia cells with 
significant ROS generation (Büyükavcı et al., 2006).  
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Figure 2.15: The cycle of reactive oxygen species induced by external stimuli and its 
fate in the intracellular environment. (Trachootham et al.,2009) 
2.8 DNA damage response 
 
Figure 2.16: The overview of the DNA damage response signal. DNA damage triggers 
the signals followed by sensors, transducers and finally to the effectors that caused the 
occurrence of cell cycle disruption, apoptosis, transcription process and DNA repair 
mechanism. (Zhou and Elledge,2000) 
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Human body can have tens of thousands of DNA lesions each day (Lindahl et al., 2000). 
Damage to the DNA can result in the blockage of gene replication and transcription 
when DNA are not being repaired. Unrepaired DNA can lead to mutations and serious 
abnormality to the cells survival. 
Hence, in order to fight the threats caused by DNA damage, cells can react in different 
ways when DNA damage occurred in the cells. Commonly, the mechanisms of DNA 
repair and cell cycle checkpoints will be activated as to arrest the cells in certain phases 
of cell cycle and perform DNA repair on the damaged DNA. However, cells that 
possess damaged DNA and cannot be repaired in this stage will be eliminated from the 
population by programmed cell death (Roos et al., 2006).  
Different molecular mechanisms of apoptosis can be stimulated based on the chemical 
basis of DNA lesion and the way it is process and detected by the cells (Roos et al., 
2013). DNA damage triggers the most upstream DNA damage response kinases, ATM 
(ataxia-telangiectasia mutated), ATR (ataxia telangiectasia and Rad3 related) and DNA- 
dependent protein kinases (DNA-PKcs) in mammalian cells where ATM and DNA-
PKcs are activated by double-stranded DNA breaks (DSBs) while ATR responds to 
broad range of DNA damage which include DSBs and other types of DNA lesions. 
(Marechal et al., 2013).  
53BP1 and BRCA1 are prominent mediators of ATM-controlled responses that are 
involved in cell cycle S-phase checkpoint, G2/M phase, apoptosis, cell proliferation and 
DNA damage repair (Deng, 2006; Ward et al., 2003). Proteins such as Chk2 will be 
phosphorylated by ATM kinase which will further phosphorylate protein phosphatase 
CDC25A that leads to cell cycle arrest in response to DNA damage in the cells (Furnari 
et al., 1997). 
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One of the characteristics that contribute to the development of cancer is the impairment 
of DNA damage response which highlighted the roles of DDR genes as tumor 
suppressor genes (Hanahan et al., 2011). The expression of DDR elements in cancer 
cells have resulted in the failure of DNA-damaging chemo- and radiotherapy due to the 
reason that cancer cells are highly dependent on these DDR elements for survival.  
Hence, the inhibition of DDR provides a platform for the exploitation of cancer cells 
that are highly dependent to the action of DDR elements for therapeutic purpose and 
also helps to solve the problem related to the resistance of tumour cells to DNA-
damaging chemotherapy (Curtin, 2013).  This exploitation provides the potential to use 
DDR inhibitors in combination with DNA-damaging therapeutics agents in radio- and 
chemo- therapy to improve the efficacy of DNA-damaging therapeutics agents in its 
antitumor activity (O’Connor, 2015). However, there are various challenges involved in 
the approach to combine DDR inhibitors and DNA-damaging therapeutics agents for 
cancer therapy. 
2.9 Proteomics in cancer research 
Genomic studies have provided us new information about biomarkers, therapeutics 
targets and mechanisms of cancer development by measuring the sequence, copy 
number changes in gene expression. However, investigation of proteins products can 
provide us with deeper understanding about cancer because protein expression shows 
significant translational and post-translational regulation of protein levels and functions. 
Proteome is the set of proteins derived from the translation of all protein coding genes 
by a cell, tissue or organism. It provides us with the understanding of the gene functions. 
Proteomics can be categorized into three areas, large scale protein micro 
characterization for the identification of proteins and its post-translational modifications, 
differential expression of proteins for different application in diseases, and protein-
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protein interactions study. These understandings will provide a better understanding on 
the proteins biochemistry and mechanisms which help in different aspects of a certain 
disease. 
Proteomics has emerged as an important tool in detecting physiological condition, 
change in a system in response to external stimuli, mutations and adaptations. Studies 
on the biospecimens from cancer patients can help us to understand and monitor tumor 
pathogenesis and detection of novel targets for cancer treatment. One of the essential 
goals of proteomic technique application is to adapt this technique for regular diagnostic 
and prognostic usage in the clinical laboratories and for the assessment of different 
cancer therapeutic regimens (Sallam, 2015).  
This technique can be used to investigate changes in global protein profiles and protein 
alteration as potential drug targets. Proteomics also allow the identification of post-
translational modifications, and sequence variants (Mann et al., 2003; Zhang et al., 
2011). Different proteomic analytical tools have been developed such as 1-dimensional 
and 2-dimensional gel electrophoresis, and mass-spectrometry based application which 
allows quantitative and qualitative analysis of diseases related whole proteome (Altaf 
Hussain et al., 2012). Development of protein microarray, a high-throughput technology 
has been really helpful to measure the expression of thousands of proteins 
simultaneously.  
In general, two different types of proteomic analysis methods have applied which 
include, top-down proteomic approach and bottom-up proteomic approach. The top-
down proteomic involved the analysis of intact proteins while bottom-up approach will 
help to identify proteins based on its peptides, a result of proteolytic digestion. An 
established method in top-down approach is the two-dimensional gel electrophoresis 
which uses the protein staining intensity to observe the changes in protein profiles. Then, 
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protein of interests will be excised from the gel for proteolytic digestion for analysis by 
mass spectrometry. Data from the peptide mass and fragmentation patterns will be used 
for protein database search for protein identification. However, a top-down strategy has 
its own limitations such as the low detection limit, difficulty in fragmenting large 
analytes, problems in resolving proteins of certain pH, and problems with protein 
solubility.  
Hence, the bottom-up proteomic approach is used for protein identification. This 
involved the usage of multi-dimensional LC/MS/MS by performing proteolysis of 
complex proteins then separation of peptides using chromatography technique prior to 
MS/MS sequencing. Current improvement in this method allows the sequencing of 
peptides by data-dependent data acquisition. Spectra from the MS/MS fragmentation of 
selected ions will be used in the sequencing and identification of proteins.  
 
Figure 2.17: A) Bottom up approach and B) Top down approach of protein 
identification in LC/MS/MS proteomic approach. (Kellie et al.,2016) 
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Proteomic studies offer new opportunities in cancer biomarker discovery, monitoring 
cancer progression, investigating the efficacy of cancer treatment, discovering new 
therapeutic targets and understanding the mechanisms underlying the disease. Plasma 
samples from mouse models and human have been used to study the lung cancer plasma 
protein signatures and study has shown that the mouse models are relevant to human 
lung cancer of the lung cancer plasma protein signatures (Taguchi et al., 2011). EGFR 
signature was identified in the plasma with other biomarkers, SFTPB and WFDC2. 
These biomarkers are significantly different in lung cancer models in comparison with 
controls.  
Another study on ovarian cancer also showed that proteomics has the potential to be 
used as a tool for routine screening of ovarian cancer by creating a template for 
proteomic-based cancer biomarkers discovery, for early detection of epithelial ovarian 
cancer and observing the treatment effect of epithelial ovarian cancer (Elschenbroich et 
al., 2011). A recent study has also applied proteomic technique to detect autoantibodies 
using microarray for the detection of ovarian biomarkers (Anderson et al., 2015).   
In this study, proteomics technique is being applied to study the relative protein 
abundance that reflects the protein expression in cancer cells as an effect of the action of 
helichrysetin. The information provided by this technique will help in the discovery of 
new therapeutic target of this potential anti-cancer agent. 
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Pure compound 
Helichrysetin was obtained from BioBioPha Co. Ltd (China) that is isolated from the 
plant of Alpinia galanga. 
3.2 Cell culture 
Human lung adenocarcinoma cell line (A549), human cervical carcinoma cell line (Ca 
Ski), human breast adenocarcinoma cell line (MCF-7), human fetal lung fibroblast cell 
line (MRC-5), and human colorectal adenocarcinoma cell line (HT 29) were obtained 
from American Type Culture Collection (ATCC, USA). The cells were cultured in 
RPMI-1640 (Roswell Park Memorial Institute) supplemented with 10% fetal bovine 
serum (FBS), 2% penicillin/streptomycin, and 1% amphotericin- B for A549, Ca Ski 
and MCF-7 cells while McCoy’s 5A and Eagle’s Minimum Essential Media (EMEM) 
were used for HT-29 and MRC-5 cells respectively with supplement stated above. Cells 
were maintained in 5% carbon dioxide (CO2) atmosphere at temperature of 37°C, 
humidified incubator in tissue culture flasks. 
3.3 MTT assay 
Cells were seeded in 96-well sterile culture plate at a concentration of 3 X 10
4
 cells/ml. 
The cells seeded were incubated overnight for adherence of cells to the surface of the 
culture plate. After the overnight incubation, media was removed from the culture plate 
wells and fresh media (with 0.5% DMSO as a vehicle) containing helichrysetin with 
concentration of 1.56 µg/ml, 3.125 µg/ml, 6.25 µg/ml, 12.5 µg/ml, 25 µg/ml, 50 µg/ml, 
100 µg/ml were added to the cells for treatment. Treatments were done for 24 hours, 48 
hours, and 72 hours. Doxorubicin was used as positive control. MTT assay was carried 
out as described by Mosmann with modifications. Upon treatment, 20 µl of MTT 
solution was added into 96 wells with 4 hours incubation in condition of 5% CO2 and at 
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temperature of 37°C. The media was later discarded and 150 µl DMSO was added to 
dissolve the formazan crystals. Absorbance was measured as below using Synergy H1 
Hybrid microplate reader: 
Abs570nm- Abs630nm= Abstreatment/control 
The percentage of inhibition by helichrysetin was calculated as: 
Abscontrol-Abstreatment  X  100 = _____ % 
Abscontrol 
IC50 values were obtained by determining the concentration at which 50% of the cell 
population is inhibited by helichrysetin.  
3.4 Phase contrast microscopy 
Cells were seeded at the concentration of 5 X 10
4
 cells/ ml into a sterile tissue culture 
plate and incubated at 5% CO2 and 37°C, overnight for cell adhesion. After overnight 
adhesion, cells were treated with helichrysetin at three time points, 24 hours, 48 hours 
and 72 hours. Then, the cells were observed under the phase microscope (Zeiss Axio 
Vert. A1) for changes in morphological features such as changes in cell volume, 
detachment, and rounding. 
3.5 Nuclear morphological assessment by DAPI staining  
Cells were plated in tissue culture plate at a concentration of 5 X 10
4
 cells/ ml into a 
sterile tissue culture plate and incubated at 5% CO2 and 37°C, overnight for cell 
adhesion. Then, cells were treated with helichrysetin at concentration of 15 µg/ml for 24 
hours and harvested for staining by 4’,6-diamidino-2-phenylindole (DAPI) staining. 
Cells were washed with phosphate buffered saline (PBS) and fixed in 4% formaldehyde. 
After fixing, cells were resuspended in DAPI solution (0.2 µg/ml), 0.1% Triton X 100 
and incubated for 5 min in the dark. The cells were then spotted on the slide and air 
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dried. Nuclear morphological changes such as chromatin condensation and nuclear 
fragmentation were examined under the fluorescence microscope (Leica) at 40X 
magnification. 
3.6 Annexin V FITC assay for apoptosis detection 
Annexin V FITC assay was performed using the FITC Annexin V Apoptosis Detection 
Kit by BD Biosciences, USA. 4 X 10
5
 cells/well were plated in culture plates and left 
overnight for adhesion. Then, the treatment was done to examine the effect of 
helichrysetin on the cells in a time and dose- dependent manner.  After treatment, the 
cells were harvested and washed with PBS. Cell pellet was resuspended in 1X Annexin 
V binding buffer, then, stained with Annexin V and propidium iodide (PI) for 15 min at 
room temperature in the dark. The analysis was performed using Accuri C6 flow 
cytometer. Cell population was observed by its quadrant statistics given the lower left 
quadrant as the viable cells population, lower right quadrant as the early apoptotic cells, 
upper right quadrant as the secondary necrotic or late apoptotic cells and upper left the 
primary necrosis population. 
 
Figure 3.1: Cell population quadrant from flow cytometry analysis 
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3.7 Assay for Mitochondrial Membrane Potential 
Assay for mitochondrial membrane potential was performed using the BD Mitoscreen 
Mitochondrial Membrane Potential Kit. Cells were plated in sterile culture plate at a 
concentration of 8 X 10
4
 and incubated for 24 hours for cell adherence. Dose and time- 
dependent effect of helichrysetin on cells were evaluated. The cells were harvested and 
washed with PBS and then stained with JC-1 BD Mitoscreen Kit for 15 min at 37°C. 
Unbound dye was removed by washing with 1X assay buffer, then, the cell pellet was 
resuspended in 1X assay buffer for analysis with flow cytometer (Accuri C6). The 
density plot of this assay was divided into two regions, apoptotic and non-apoptotic 
cells. 
3.8 TUNEL assay 
Internucleosomal DNA fragmentation was detected using the APO-BrDU TUNEL 
assay kit (Invitrogen). Cells were plated overnight and treated at different time intervals 
and different concentrations of helichrysetin. At the end of treatement, cells were 
harvested and washed with PBS.  Then, the cells were fixed with 1% (w/v) 
paraformaldehyde on ice for 15 min. Cells were then spinned and washed with PBS 
twice. Ice cold ethanol was added to the cells for fixation for at least 30 min in -20°C. 
After fixation, ethanol was removed and the cells were washed with wash buffer.  Cells 
were incubated in DNA-labeling solution for 60 min at 37°C, rinsed and then labelled 
with antibody solution for 30 min at room temperature. Before analysis, propidium 
iodide/RNase A staining buffer was added to the sample and analysed using flow 
cytometry (Accuri C6). 
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3.9 Cell cycle analysis 
8 X 10
4 
cells/mL were plated in the sterile cell culture plate and allowed to adhere 
overnight. The cells were treated with helichrysetin for 24, 48 and 72 hours. After 
treatment, the cells were harvested and washed with cold PBS. Then, the cells were 
fixed with 70% ethanol overnight at -20°C. Cells were then pelleted and washed with 
cold PBS then stained with propidium iodide staining solution containing 0.1% Triton-
X- 100, 0.1% sodium citrate, 100 µg/mL RNase and 50 µg/mL propidium iodide for 30 
minutes in the dark. Then, the cells were separated using the cell strainer and analysed 
using Accuri C6 flow cytometer. Results were analysed using ModFit software. 
3.10 Western blotting 
50 µg of total cell lysates were separated by 5% stacking gel and 12% separating gel in 
acrylamide gel electrophoresis. Proteins were transferred onto nitrocellulose membrane 
and blocked for 2 hour with bovine serum albumin at room temperature. The membrane 
was incubated with primary antibody (1:1000) at 4°C overnight. Then, the membrane 
was incubated with peroxidase-conjugated secondary antibody (1:2000) and visualized 
using chemiluminescence.  
3.11 In solution digestion 
50 µg of cell protein extract was reduced with 10 mM dithiotreitol in 8M urea and 
50mM Tris buffer at 37°C for 1 hour and then alkylated with 50 mM iodoacetamide 8M 
urea and 50mM Tris buffer for 30 minutes in the dark at room temperature finally 
stopped with dithiotreitol. A little benzonase was added into the solution and incubated 
for 2 hours at room temperature.  Then, Lys-C was added (1:200) to the solution and 
incubated for 4 hours at room temperature and finally trypsin (1:50) was added and 
incubated overnight at 37°C. 
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3.12 iTRAQ labeling of digested peptides 
Salts and detergents were removed from the resulting peptides of digested proteins 
using Sep-Pak C18 cartridges and dried in vacuum. Peptides were labeled according to 
the manufacturer’s instructions with 114, 115, 116 and 117 isobaric tag 4-plex iTRAQ 
reagents for control, 6 hours, 24 hours and 48 hours treated sample respectively. Four 
samples were pooled together and dried with vacuum concentrator.  
3.13 Strong cation exchange chromatography of peptide samples 
Pooled labeled peptides were resuspended in 200 µL 10mM KH2PO4, pH 2.65, 25% 
acetonitrile (Buffer A) and loaded onto Polysulfoethyl A, 4.6 × 200mm column (Poly 
LC) containing 5 µm polysufoethyl aspartamide beads with 300Å pore size and at a 
flow rate of 1ml/min. Peptides were detected with UV at 214nm. Gradient was 
developed in 20 minutes to 15% Buffer B (1M KCl in Buffer A, pH 2.65), 10 minutes to 
30% Buffer B, 5 minutes to 50% Buffer B, 1 minute to 100% Buffer B. Fractions were 
collected every 30 seconds and desalted using Sep-Pak C18 cartridges then dried with 
vacuum concentrator. 
3.14 Shotgun proteomic identifications 
NanoLC−nanoESI-MS/MS analysis was performed on a nanoAcquity system (Waters, 
Milford, MA) in data-dependent mode, connected to the LTQ Orbitrap Velos hybrid 
mass spectrometer (Thermo Electron, Bremen, Germany) equipped with PicoView 
nanospray interface (New Objective, Woburn, MA). Peptide samples were loaded onto 
a 75 μm ID, 25 cm length C18 BEH column (Waters, Milford, MA) with a pore of 130 
Å. Peptides were separated with gradient from 5% to 40% solvent B (acetonitrile with 
0.1% formic acid) for 120 min at a flow rate of 300 nL/min. 0.1% formic acid in water 
was used as solvent A. Full scan of MS spectra were acquired in the orbitrap (m/z 350–
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1600) with 60K resolution at m/z 400. The top 10 ions were isolated for HCD MS/MS 
fragmentation and detected in the orbitrap with dynamic exclusion of 60s. MS/MS 
analysis was done with resolution of 7500, isolation window of 2 m/z and a target value 
of 50000 ions. Normalized collision energy of 40% and activation time of 0.1 ms were 
used for fragmentation. Unrecognized and single charged ions were excluded from the 
analysis. 
3.15 Protein identification and quantitation 
Protein identification and quantitation were carried out using Thermo Proteome 
Discoverer (PD 1.4.1.14.) software against Swiss-Prot human protein database 
(Human_uniprot2015001, 27 October 2015, 148,986 entries). The search was 
performed with two trypsin missed cleavage allowed, fixed modications of 
carbamidomethylation of cysteine residues, iTRAQ 4plex at lysine residues and N-
terminal proteolytic peptides, variable modifications of oxidation at methionine residues. 
For target decoy PSM validator, strict target FDR was set at 0.01 and relaxed target 
FDR at 0.05. 
3.16 Statistical analysis 
Proteins present in both biological replicates were identified with calculations of 
114:115, 114:116, and 114:117 protein ratios. Average protein ratios of each protein 
were normalized by conversion to log2 average protein ratio and then converted to z-
score using the formula as given below. Z-score determines the standard deviation of 
protein ratio from the mean and the proteins were then selected for further analysis with 
the cut-off, z-score >1.960σ or <-1.960σ.  
Z-score = Log2 protein ratio – average of (log2 all protein ratio) 
  Standard deviation of (log2 all protein ratio) 
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3.17 Functional annotation  
Differentially expressed proteins derived from the calculation of Z-score of proteins 
from each time point were categorized based on their gene names. These genes were 
annotated based on its biological processes, molecular functions and cellular 
components by gene ontology human genome wide annotation for human, org.Hs.eg.db 
package (Carlson et al., 2013) using an R package, clusterProfiler (v. 3.0.5) (Yu et al., 
2012) (http://www.bioconductor.org) with p-value 0.01 using the Benjamini Hochberg 
method to control the false discovery rate. To perform semantic comparison of gene 
ontology terms in order to eliminate GO terms redundancy, GoSemSim package 
(v.2.0.3) (Yu et al., 2010) was used in R. 
3.18 Ingenuity Pathway Analysis (IPA) 
Data from the statistical analysis of significantly altered proteins were selected for 
elucidation of pathway involved in the action of helichrysetin using Ingenuity Pathway 
Analysis (Ingenuity Systems, www.ingenuity.com). Datasets were analyzed using the 
gene identifiers and its log2 protein ratios to represent the protein expression value. Top 
10 canonical pathways were identified from the library of IPA. The top 10 canonical 
pathways represent the datasets that are most significantly matched to pathways 
involved in the database. The significance of the matched dataset to the canonical 
pathways from the library of IPA was determined by the ratio of the number of genes 
from the dataset that mapped to the canonical pathways in IPA database divided by the 
total number of genes involved in the particular canonical pathways.  The p-value was 
calculated using the Fischer’s exact test which determines the probability of an 
association that occur by chance. To further understand the changes of the expression in 
this dataset, upstream regulators were also predicted using IPA. Results from the 
upstream regulator prediction and determination of the canonical pathways were 
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combined to elucidate the biological activities that were involved in the action of 
helichrysetin. To better display the molecular mechanisms involved in the action of 
helichrysetin on cancer cells, the biological pathways were built using the IPA Pathway 
Builder.  
 
Figure 3.2: Summary of workflow involving the study of helichrysetin on cancer cell 
lines. 
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CHAPTER 4: RESULTS 
4.1 Growth inhibition activity of helichrysetin on selected cancer cell lines 
Four selected cancer cell lines were treated with helichrysetin at different concentrations, 
1.56 µg/ml, 3.125 µg/ml, 6.25 µg/ml, 12.5 µg/ml, 25 µg/ml, 50 µg/ml, 100 µg/ml for 72 
hours to evaluate the growth inhibition of helichrysetin using the MTT assay. Results 
showed, as the concentration of helichrysetin increased, the percentage of growth 
inhibition also increased significantly in a dose-dependent manner (Figure 4.1). This 
growth impairment is in comparison with its negative control. No significant cell 
inhibitory activity was observed in the vehicle/DMSO- treated cells. The results of MTT 
assay revealed that helichrysetin inhibits the cells with the IC50 values of 50.72 ± 1.26 
µM, 31.02 ± 0.45 µM, 97.35 ± 1.71 µM, and 102.94 ± 2.20 µM on A549, Ca Ski, MCF-
7 and HT-29 cell line respectively. Results showed that helichrysetin is most effective 
towards A549 and Ca Ski cell lines with its IC50 values of 50 µM and below. A549 cell 
line was selected for further investigation.  
The inhibitory activity of helichrysetin was also tested on MRC-5 cell line which is 
human normal lung fibroblast and the result showed IC50 value of 123.66 ± 0.05 µM that 
is below the active concentration. Next, we determine the growth inhibitory activity by 
helichrysetin on A549 cell line at time points, 6, 12, 24 and 48 hours. The percentage of 
inhibition on A549 cell line increased in a time-dependent manner from 12.28%, 
25.95%, 38.57% and 51.69% when treated at the concentration of 50 µM (15 µg/ml) 
(Table 4.2).  
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Figure 4.1: MTT assay to assess growth inhibitory activity of helichrysetin on four 
selected cancer cell lines. Cells were treated with helichrysetin from 1.56 µg/ml to 
100.00 µg/ml and the percentage of inhibition was calculated in comparison with 
untreated control. Data represents the means ± SD. The results shown represent three 
independent experiments. *p value < 0.05 vs untreated control. 
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Table 4.1: IC50 values for helichrysetin by MTT assay in selected cancer cell lines 
 
Table 4.2: Time-dependent inhibition of helichrysetin in A549 cell line by MTT assay. 
Treatment duration (hour) Percentage of inhibition 
6 12.38 
12 25.95 
24 38.57 
48 51.69 
 
 
 
 
 
 
 
Cell Line Cell Type Half maximal inhibitor 
concentration 
IC50 (µM) 
A549 Human lung adenocarcinoma 50.72 ± 1.26 
(14.52 ± 0.36 µg/ml) 
Ca Ski Human cervical carcinoma 31.02 ± 0.45 
(8.88 ± 0.13 µg/ml) 
MCF-7 Human breast adenocarcinoma 97.35 ± 1.71 
(29.47 ± 0.63 µg/ml) 
HT-29 Human colon adenocarcinoma 102.94 ± 2.20 
(27.87 ± 0.49 µg/ml) 
MRC-5 Human lung fibroblast 123.66 ± 0.05 
(35.40 ± 1.47 µg/ml) 
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4.2 Helichrysetin-treated A549 cells morphological study 
Cellular morphology and cell nuclear morphology changes were assessed using phase 
contrast microscopy and fluorescence microscopy with DAPI staining.  
4.2.1 Cell morphological assessment by phase contrast microscopy 
The effect of helichrysetin on the A549 cells morphology was evaluated using phase 
contrast microscopy. A549 cells were treated at concentration 5 µg/ml, 15 µg/ml and 20 
µg/ml helichrysetin and at time point 24 hours, 48 hours and 72 hours. Phase contrast 
microscopy showed that cells treated with helichrysetin detached from the substratum of 
the culture surface that caused the increase in the number of floating cells (Figure 4.2). 
Total cell from the population that detached from culture surface increased as the 
concentration of the helichrysetin increased from untreated samples, 5 µg/ml, 15 µg/ml 
and 20 µg/ml of helichrysetin. Detachment of cells also occurred in a time-dependent 
manner all at time 24 hours, 48 hours and 72 hours in comparison with untreated cell 
samples.  
Results of the time-dependent study (Figure 4.3) showed that cells start to shrink after 6 
hours of treatment with 15 µg/ml helichrysetin. After 12-24 hours of treatment, A549 
cells become rounded and some of the cells started to lose its attachment to the flask 
displayed by the bright cells. Finally after 48 hours of treatment, cells detached from the 
flask appearing as rounded and bright cells that loss its anchoring to the bottom of the 
flask.
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Figure 4.2: Cell morphological assessment of A549 cells treated with helichrysetin at different time points (a) and concentrations (b). a) Time-
dependent study i) Untreated sample ii) 24 hours treatment iii) 48 hours treatment iv) 72 hours treatment b) Dose-dependent study i) Untreated A549 
cells ii) A549 cells treated with 5 µg/ml helichrysetin iii) A549 cells treated with 15 µg/ml helichrysetin iv) A549 cells treated with 20 µg/ml 
helichrysetin.
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Figure 4.3: Cell morphological assessment at 40× magnification, a time-dependent 
study.  Black arrows indicate cells that showed morphological changes due to treatment 
of helichrysetin at 15µg/ml at different time points.  
4.2.2 Fluorescence microscopy evaluation of nuclear morphological changes by 
DAPI staining 
A549 cells were treated with 15 µg/ml helichrysetin for 24 hours to observe its effect on 
the cell nuclear morphology. Figure 4.4a showed the untreated A549 cells stained with 
DAPI fluorescent stain while Figure 4.4b displayed the nuclear morphology of 
helichrysetin-treated A549 cells. As shown in the fluorescence microscopy image in 
Figure 4.4, there were no visible bright blue cells in the untreated samples (Figure 4.4a) 
and the bright blue fluorescence can be seen in A549 cells treated with 15 µg/ml 
helichrysetin at time point of 24 hours (Figure 4.4b).  
A549 cells cultured in the absence of helichrysetin showed intact nuclei due to the low 
permeability of the DAPI stain through the cell membranes of healthy cells hence 
contributed to the low fluorescence in the untreated A549 cells. Bright blue cells in 
Figure 4.4b are present due to the highly concentrated nature of the cell DNA in 
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helichrysetin-treated cells which prove that the cells exhibited nuclear fragmentation 
and chromatin condensation. This observation clearly displays the occurrence of 
apoptotic cell death in helichrysetin-treated cells. 
 
Figure 4.4: Nuclear morphological assessment of A549 cells treated with 50 µM of 
helichrysetin for 24 hours by DAPI staining. Cells with nuclear morphological changes 
are indicated by bright blue cells in the treated sample (b). a) Untreated A549 cells b) 
A549 cells treated with 50 µM helichrysetin. 
4.3 Flow cytometry study of apoptosis and cell cycle analysis  
4.3.1 Detection of early and late apoptosis by evaluation of cell membrane integrity 
Figure 4.5 and 4.6 showed the density plot from flow cytometry analysis of apoptotic 
induction effect of helichrysetin on A549 cells in a dose- and time- dependent study. 
Percentage of the live, early apoptotic, late apoptotic and necrotic cells are represented 
in four different quadrants in the density plot, lower left, lower right, upper left and 
upper right quadrant respectively. The percentage of cell population in each quadrant is 
summarized into bar chart in Figure 4.7 and 4.8.  
As shown in Figure 4.7, percentage of live cells in the dose-dependent study decreased 
as the concentration of helichrysetin increased from 5 µg/ml to 20 µg/ml in comparison 
with untreated control. While the percentage of cell in the early apoptotic, late apoptotic, 
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and necrotic quadrants increased in a dose-dependent manner. The percentage of early 
apoptotic cells increased from 2.65 ± 0.31% (control) to 2.78 ± 0.21%, 14.98 ± 0.79%, 
and 28.55 ± 1.19% as the concentration increased from 5 µg/ml to 20 µg/ml. Annexin 
V/PI double stained cells increased from 3.74 ± 0.17% (control) to 4.39 ± 0.60%, 8.40 ± 
1.02%, and 18.29 ± 2.58% for dose-dependent study. This proves that helichrysetin has 
the ability to induce apoptosis in A549 cells and its effect is more pronounced at the 
concentration of 15 µg/ml and 20 µg/ml causing more cells to undergo early and late 
apoptosis. 
Upon treatment of A549 cells at 15 µg/ml, the percentage of viable cells decreased in a 
time-dependent manner in comparison with untreated control. Helichrysetin caused 
great effect on treated A549 cells by inducing early apoptosis at IC50 in a time-
dependent manner. However, its effect is not pronounced in inducing late apoptosis in 
A549 cells given the increase in the percentage of cells in late apoptotic stage from 24 
hours to 48 hours. After treatment with helichrysetin for 24 hours, 48 hours and 72 
hours, results showed increase of early apoptotic cells from 2.03 ± 0.18% (control) to 
11.15 ± 3.53%, 15.73 ± 1.18%, and 26.92 ± 1.38% while percentages of late apoptotic 
cells are 3.99 ± 0.30% to 6.33 ± 0.65%, 11.70 ± 0.90% and 11.87 ± 1.05% respectively. 
The percentage of cells in both early and late apoptotic stages were combined and 
summarized in Figure 4.9 and 4.10 for dose- and time- dependent studies. The results 
are summarized as the percentage Annexin-V positive cells indicating all cells that 
undergo apoptosis upon treatment with helichrysetin. As shown in Figure 4.9, the 
percentage of Annexin-V positive cells increased in a dose-dependent manner and it is 
significantly different compared to untreated control at the concentration of 15 µg/ml 
and 20 µg/ml. This shows that the effect of helichrysetin to induce apoptosis in A549 
cells is significant at 15 µg/ml and 20 µg/ml upon treatment for 72 hours. At IC50, the 
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effect of helichrysetin on A549 cells is significant at time 24 hours, 48 hours and 72 
hours.  
 
Figure 4.5: Apoptotic induction effect of helichrysetin on A549 cells in a dose-
dependent study. Density plots showed the cell population in different quadrants, LL- 
Live cells, LR- early apoptotic cells, UR- late apoptotic cells, UL- secondary necrotic 
cells. a) Untreated A549 cells b) A549 cells treated with 5 µg/ml helichrysetin c) A549 
cells treated with 15 µg/ml helichrysetin d) A549 cells treated with 20 µg/ml 
helichrysetin 
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Figure 4.6: Apoptotic induction effect of helichrysetin on A549 cells in a time-
dependent study. Density plots showed the cell population in different quadrants, LL- 
Live cells, LR- early apoptotic cells, UR- late apoptotic cells, UL- secondary necrotic 
cells. a) Untreated A549 cells b) A549 cells treated with 15 µg/ml helichrysetin for 24 
hours c) A549 cells treated with 15 µg/ml helichrysetin for 48 hours d) A549 cells 
treated with 15 µg/ml helichrysetin for 72 hours 
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Figure 4.7: Percentage of cell population that consists of live cells, early apoptotic cells, 
late apoptotic cells and necrotic cells in dose-dependent study detected by Annexin V-
FITC/PI assay. Cells were treated with 5 µg/ml, 15 µg/ml and 20 µg/ml of helichrysetin 
for 72 hours. Data represents the means ± SD. The results shown represent three 
independent experiments. 
 
 
 
 
 
 
 
 60 
 
 
Figure 4.8: Percentage of cell population that consists of live cells, early apoptotic cells, 
late apoptotic cells and necrotic cells in time-dependent study detected by Annexin V-
FITC/PI assay. Cells were treated with 15 µg/ml of helichrysetin at 24 hours, 48 hours 
and 72 hours. Data represents the means ± SD. The results shown represent three 
independent experiments. 
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Figure 4.9: Percentage of apoptotic cells represented by the Annexin V positive-stained 
cells that consists of early and late apoptotic cells in dose-dependent study detected by 
Annexin V-FITC/PI assay. Cells were treated with 5 µg/ml, 15 µg/ml and 20 µg/ml of 
helichrysetin for 72 hours. Data represents the means ± SD. *p value < 0.05 vs untreated 
control. The results shown represent three independent experiments. 
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Figure 4.10: Percentage of apoptotic cells represented by the Annexin V positive-
stained cells that consists of early and late apoptotic cells in time-dependent study 
detected by Annexin V-FITC/PI assay. Cells were treated with 15 µg/ml of 
helichrysetin at 24 hours, 48 hours and 72 hours. Data represents the means ± SD. *p 
value < 0.05 vs untreated control. The results shown represent three independent 
experiments. 
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4.3.2 Analysis of mitochondrial membrane potential for detection of apoptosis in 
A549 cells 
Evidence for the effect of helichrysetin on the mitochondrial membrane potential of 
A549 cells was obtained using JC-1 mitochondrial membrane potential assay analyzed 
by flow cytometer. Density plot in Figure 4.11 and Figure 4.12 displayed the 
distribution of viable (top region) and apoptotic cells (bottom region) in the 
mitochondrial membrane potential analysis. Apoptotic cells are indicated by cells that 
have collapsed mitochondrial membrane potential which is related to the mitochondria-
mediated apoptosis. 
In the dose-dependent experiment, the percentage of cells in the apoptotic cells (bottom 
region) increased when the dosage of helichrysetin increased from 5 µg/ml to 20 µg/ml. 
The increase in the percentage of cells in the apoptosis region indicates the dose-
dependent decrease in mitochondrial membrane potential. Collapse of mitochondrial 
membrane potential is a result of increase fluorescence intensity of monomeric JC-1 in 
the cytosolic part of A549 cells contributing to the increase in the green fluorescence in 
flow cytometry analysis. The percentage of apoptotic cells increased drastically at 
concentration of 15 µg/ml and 20 µg/ml. 
Treatment with helichrysetin at IC50 at different time points showed that exposure of 
A549 cells to helichrysetin will cause the reduction in the mitochondrial membrane 
potential in the time-dependent manner. The percentage of viable cells decreased upon 
24 hours and 48 hours treatment. Approximately one-half of the cell populations 
undergo apoptosis after exposure with helichrysetin for 48 hours. This suggests that 
helichrysetin is capable of inducing mitochondria-mediated apoptosis in A549 cells 
indicates by the changes of mitochondrial membrane potential. 
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Figure 4.11: Treatment of A549 cells with varying concentrations of helichrysetin causes the collapse of mitochondrial membrane potential. Cell 
distribution in mitochondrial membrane potential assay analysed with flow cytometer in a dose-dependent study. Cells were exposed to helichrysetin at 
5 µg/ml, 15 µg/ml and 20 µg/ml for 72 hours a) Untreated A549 cells b) A549 cells treated with 5 µg/ml helichrysetin c) A549 cells treated with 15 
µg/ml helichrysetin d) A549 cells treated with 20 µg/ml helichrysetin  
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Figure 4.12: Exposure of A549 cells at different duration with helichrysetin at IC50 concentration causes the collapse of mitochondrial membrane 
potential. Cell distribution in mitochondrial membrane potential assay analyzed with flow cytometer in a time-dependent study. Cells were exposed to 
15 µg/ml helichrysetin for 24 hours, 48 hours and 72 hours. a) Untreated A549 cells b) A549 cells treated with 15 µg/ml helichrysetin for 24 hours c) 
A549 cells treated with 15 µg/ml helichrysetin for 48 hours d) A549 cells treated with 15 µg/ml helichrysetin for 72 hours
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4.3.3 Detection of apoptotic DNA fragmentation by TUNEL assay 
Apoptotic DNA fragmentation was detected using TUNEL assay by flow cytometer. 
Figure 4.13 and Figure 4.14 displayed the results of apoptotic DNA fragmentation of 
A549 cells upon treatment with helichrysetin at different concentrations and time points. 
Plots in Figure 4.15 showed the distribution of live cells and apoptotic cells with 
fragmented DNA for the dose-dependent study and it is cleared that the increase in the 
concentration of helichrysetin from 5 µg/ml to 20 µg/ml caused increase DNA 
fragmentation in A549 cells. As shown in Figure 4.16, the treatment of helichrysetin at 
IC50 at time 24 hours, 48 hours and 72 hours resulted in the increase of apoptotic cells 
with DNA fragmentation. 
There is a significant increase in the portion of TUNEL positive cells which are the 
apoptotic cells with fragmented DNA from 0.61% to 1.28%, 42.63% and 82.34% as the 
concentration of helichrysetin increased (Figure 4.13). When treated at IC50 for 24 hours, 
48 hours and 72 hours, the percentage of TUNEL positive cells showed a significant 
elevation from 0.61% to 2.76%, 15.16%, and 41.29% (Figure 4.14). This proves that 
helichrysetin can cause the occurrence of DNA strand break in A549 cells and its effect 
is significant with increase dosage and exposure time. 
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Figure 4.13: Detection of fragmented DNA from apoptotic cells by flow cytometric TUNEL assay. Density plot with cell distribution of live cells and 
apoptotic cells in a dose-dependent study. A549 cells were exposed to 5 µg/ml, 15 µg/ml and 20 µg/ml helichrysetin for 72 hours. a) Untreated A549 
cells b) A549 cells treated with 5 µg/ml helichrysetin c) A549 cells treated with 15 µg/ml helichrysetin d) A549 cells treated with 20 µg/ml 
helichrysetin. (Each figure is representative of 3 experiments) 
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Figure 4.14: Detection of fragmented DNA from apoptotic cells by flow cytometric TUNEL assay. A549 cells were exposed to helichrysetin at IC50 at 
different duration. a) Untreated A549 cells b) A549 cells treated with 15 µg/ml helichrysetin for 24 hours c) A549 cells treated with 15 µg/ml 
helichrysetin for 48 hours d) A549 cells treated with 15 µg/ml helichrysetin for 72 hours. (Each figure is representative of 3 experiments) 
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Figure 4.15: Percentage of apoptotic cells with fragmented DNA represented by 
percentage of TUNEL-positive cells. Cells were treated with 5 µg/ml, 15 µg/ml and 20 
µg/ml of helichrysetin for 72 hours. Data represents the means ± SD. *p value < 0.05 vs 
untreated control. The results shown represent the findings from three independent 
experiments. 
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Figure 4.16: Percentage of apoptotic cells with fragmented DNA represented by 
percentage of TUNEL-positive cells. Cells were exposed to helichrysetin at IC50 for 24 
hours, 48 hours and 72 hours. Data represents the means ± SD. *p value < 0.05 vs 
untreated control. The results shown represent the findings from three independent 
experiments. 
4.3.4 Cell cycle analysis of helichrysetin-treated A549 cells 
In cell cycle analysis, A549 cells were exposed to different dosage of helichrysetin, 5 
µg/ml, 15 µg/ml and 20 µg/ml for 72 hours. Results from cell cycle analysis showed 
that helichrysetin caused the accumulation of cells in the S phase of the cell cycle 
(Figure 4.17). This is shown by the significant increase in the percentage of A549 cells 
in the S phase of cell cycle.  
The elevation in the percentage of cells in S phase occurred simultaneously with a 
significant decrease of cell percentage in G0/G1 phase of the cell cycle (Figure 4.18). 
The percentage of cells in S phase increased from 16.69 ± 2.99% (untreated control) to 
26.47 ± 1.56%, 38.29 ± 0.89%, and 46.91 ± 2.62% in a dose-dependent fashion. The 
percentage of cells in G0/G1 phase reduced from 73.38 ± 3.57% (untreated control) to 
69.43 ± 0.49%, 49.03 ± 1.43%, and 43.33 ± 2.05% in a dose-dependent manner. 
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Results from cell cycle analysis revealed that helichrysetin has an effect on the cell 
cycle of A549 cells by causing the accumulation of cells in the S phase and the 
reduction of cells in the G0/G1 phase of the cell cycle. 
 
Figure 4.17: Cell cycle analysis of A549 cells treated with helichrysetin. Histogram 
showed the distribution of cells at different phases of cell cycle was determined using 
flow cytometer upon treatment with helichrysetin at different concentrations. a) 
Untreated A549 cells b) A549 cells treated with 5 µg/ml helichrysetin c) A549 cells 
treated with 15 µg/ml helichrysetin d) A549 cells treated with 20 µg/ml helichrysetin 
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Figure 4.18: Bar chart displayed the A549 cells distribution at different phases of cell 
cycle in cell cycle analysis. Cells were exposed to helichrysetin at different 
concentrations, 5 µg/ml, 15 µg/ml and 20 µg/ml for 72 hours. Data represents the means 
± SD. *p value < 0.05 vs untreated control. The results represent the findings from three 
independent experiments. 
4.3.5. Apoptotic proteins detection in helichrysetin-treated and untreated A549 
cells with western blotting 
A549 cells were treated with helichrysetin at concentration of 15 µg/ml for 6 hours, 24 
hours and 48 hours to detect specific apoptotic proteins changes. Caspases are protease 
enzymes that play important roles in the mechanisms of programmed cell death or 
apoptosis. Expression of caspase 3, caspase 8 and caspase 9 was investigated upon 
treatment with helichrysetin in comparison with untreated cells.  
Results in Figure 4.19 showed that the expression of pro-caspase 3 (6hr: 1.00; 24hr: 
1.07; 48hr: 1.33, Treated: 6hr: 1.01; 24hr: 0.89; 48hr: 0.73) was diminished upon 
treatment with helichrysetin in a time-dependent manner from 6 hours to 48 hours and 
the cleaved caspase 3 increased from 6 hours to 48 hours (6hr: 1.00; 24hr: 0.73; 48hr: 
0.53, Treated: 6hr: 1.08; 24hr: 2.29; 48hr: 3.75). Pro-caspase 8 (6hr: 1.00; 24hr: 0.78; 
 73 
 
48hr: 0.83, Treated: 6hr: 0.70; 24hr: 0.97; 48hr: 0.92) and cleaved caspase 8 (6hr: 1.00; 
24hr: 0.82; 48hr: 0.64, Treated: 6hr: 0.69; 24hr: 1.15; 48hr: 1.84) also showed the 
similar trend where both proteins showed increase expression upon treatment for 6 
hours, 24 hours and 48 hours. For caspase 9, the pro-caspase 9 showed decreased in 
expression after 6hours. 24 hours and 48 hours treatment (6hr: 1.00; 24hr: 0.96; 48hr: 
0.82, Treated: 6hr: 0.77; 24hr: 0.46; 48hr: 0.41) while cleaved caspase 9 showed 
increased expression from 6 hours to 48 hours treatment (6hr: 1.00; 24hr: 2.24; 48hr: 
2.59, Treated: 6hr: 3.11; 24hr: 3.53; 48hr: 3.58).  
Poly (ADP-ribose) polymerase (PARP) is one of the commonly used markers for the 
detection of apoptosis. As shown in Figure 4.19, the full length PARP protein 
expression decreased after treatment with helichrysetin and this effect occurs in a time-
dependent fashion (6hr: 1.00; 24hr: 0.84; 48hr: 0.80, Treated: 6hr: 0.96; 24hr: 0.78; 
48hr: 0.27). As the expression of full length PARP protein decreased, the expression of 
cleaved PARP increased upon helichrysetin treatment in a time-dependent manner (6hr: 
1.00; 24hr: 0.95; 48hr: 1.00, Treated: 6hr: 0.95; 24hr: 1.20; 48hr: 1.21).  
Upon treatment with helichysetin, there is also a release of cytochrome c into the the 
cytosol with the increase in the protein expression at 6 hours, 24 hours and 48 hours of 
treatment in comparison with vehicles at each time point. (6hr: 1.00; 24hr: 1.00; 48hr: 
1.36, Treated: 6hr: 1.58; 24hr: 1.35; 48hr: 1.67). 
Apoptosis is regulated by Bcl-2 family proteins and the proteins that are being 
investigated are Bcl-2, and Bax. Results in Figure 4.19 displayed the protein band 
intensity of Bcl-2 protein (6hr: 1.00; 24hr: 1.11; 48hr: 1.31, Treated: 6hr: 1.20; 24hr: 
0.81; 48hr: 0.54) decreasing after 24 hours and 48 hours treatment. While for Bax which 
is a pro-apoptotic protein, the expression of Bax protein increased in a time-dependent 
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manner from 6hours treatment to 24 hours (6hr: 1.00; 24hr: 1.81; 48hr: 2.47, Treated: 
6hr: 2.46; 24hr: 2.63; 48hr: 2.47).  
 
Figure 4.19: Western blotting analysis of apoptotic markers. Effects of helichrysetin on 
A549 cells were evaluated by western blotting after treatment with 50 µM helichrysetin 
at 6, 24 and 48 hours and without treatment (vehicle) at 6, 24 and 48 hours.  
 
 
 
 
 
 75 
 
4.4 Application of proteomic to investigate mechanism of action of helichrysetin 
4.4.1 Proteomic analysis of whole cell proteome from helichrysetin-treated A549 
cell 
To investigate the molecular mechanisms involved in the induction of cell death in 
A549 cancer cells by helichrysetin, quantitative proteomic analysis was performed 
using the iTRAQ labeling. Duplicate protein samples from 4 different treatments, 
untreated (control), 6 hours helichrysetin-treated sample, 24 hours helichrysetin-treated 
sample, and 48 hours helichrysetin-treated sample were labeled with iTRAQ labels 114, 
115, 116, 117, pooled and analyzed.  
A total of 3708 and 3561 proteins were identified and quantified in both first and second 
biological replicates respectively. These proteins are selected by at least 2 unique 
peptides with 1% FDR.  2645 proteins were identified and identical in both replicates 
which correspond to 1% FDR. 95% confidence level which corresponds to z-score 
of >1.960σ or < -1.960σ were used to determine differentially regulated proteins. z-
score was calculated as followed: 
z-score (protein) = Log2 protein ratio – Mean of (log2 of each protein ratio) 
   Standard deviation of (log2 of each protein ratio) 
With this criterion, differentially expressed proteins were selected from the 2645 
identified and identical proteins in both replicates from each sample.  
Following this criterion, 125 proteins, 129 proteins and 141 proteins were identified as 
differentially expressed after treatment with helichrysetin for 6 hours, 24 hours, and 48 
hours respectively. From the 6 hours helichrysetin-treated sample (115:114), 60 proteins 
were up-regulated and 65 proteins were down-regulated, the 24 hours helichrysetin-
treated sample (116:114), 45 proteins were up-regulated and 84 proteins were down-
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regulated and the 48 hours helichrysetin-treated sample (117:114), 70 proteins were up-
regulated and 71 proteins were down-regulated.  
Table 4.3: Number of proteins that are differentially up- and down- regulated in three 
samples treated with helichysetin. 
 
 
 
 
 
 
 
The differentially expressed proteins were analyzed using Ingenuity Pathway Analysis 
(IPA) software to determine canonical pathways and upstream regulators that are 
significantly linked to these proteins. Figure 4.20 showed the analysis result of top 10 
canonical pathways from comparison analysis for 6 hours, 24 hours and 48 hours 
helichrysetin-treated results that are most significant to the data set and the proteins 
involved in the pathways.  
Top 10 canonical pathways relevant to the given set of data are assembly of RNA 
polymerase III complex, cell cycle: G2/M DNA damage checkpoint regulation, NRF2-
mediated oxidative stress response, granzyme B signaling, asparaginase biosynthesis I, 
ATM signaling, GADD45 signaling, hereditary breast cancer signaling, aryl 
hydrocarbon receptor signaling and γ-linolenate biosynthesis II. 
No. of proteins 6hr 
(115:114) 
24hr 
(116:114) 
48hr 
(117:114) 
Upregulated 60 45 70 
Downregulated 65 84 71 
Total 125 129 141 
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Figure 4.20: Ingenuity Pathway Analysis for significantly regulated proteins. Top 10 canonical pathways from comparison IPA analysis for 6, 24, and 
48 hours with significance of p value < 0.05 (-log (p-value)>1.3) 
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This result revealed the important components involved in cell cycle: G2/M DNA 
damage checkpoint regulation, NRF2-mediated oxidative stress response, ATM 
signaling, GADD45 signaling and hereditary breast cancer signaling, and will be further 
investigated in this study (Table 4.4). Gene ontology analysis was performed based on 
the biological processes for all the differentially expressed proteins using R package, 
clusterProfiler and GoSemSim. Result is displayed in Figure 4.21. 
Table 4.4: List of top 10 canonical pathways and proteins that are significantly altered 
in association with the pathways. 
Top 10 canonical pathways 
Proteins involved (Gene name) 
6h 24h 48h 
Assembly of RNA Polymerase III 
Complex 
GTF3C1 
GTF3C3 
GTF3C5 
GTF3C1 
GTF3C3 
GTF3C5 
- 
Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation 
YWHAG 
YWHAE 
SFN 
CCNB1 
CDKN1A CDKN1A 
CCNB1 
NRF2-mediated Oxidative Stress 
Response 
HMOX1 
FTL 
EPHX1 
ERP29 
ABCC1 
GSTK1 
HMOX1 
FTL 
DNAJB1 
EPHX1 
 
HMOX1 
FTL 
ERP29 
EPHX1 
GSTK1 
 
Granzyme B Signaling 
LMNB1 
LMNB2 
LMNB1 
LMNB2 
LMNB1 
LMNB2 
Asparagine Biosynthesis I ASNS ASNS ASNS 
ATM Signaling 
BRAT1 
FANCD2 
CCNB1 
BRAT1 
FANCD2 
CDKN1A 
FANCD2 
CCNB1 
CDKN1A 
GADD45 Signaling 
CDK4 
CCNB1 
CDKN1A CDKN1A 
CCNB1 
Hereditary Breast Cancer Signaling 
FANCD2 
CDK4 
SFN 
CCNB1 
FANCD2 
CDKN1A 
CDK6 
FANCD2 
RB1 
CDKN1A 
CDK6 
CCNB1 
 79 
 
Aryl Hydrocarbon Receptor 
Signaling 
 
CDK4 
GSTP1 
PTGES3 
CTSD 
RB1 
ALDH3B1 
GSTK1 
 
POLA1 
CDKN1A 
CDK6 
 
CTSD 
RB1 
ALDH3B1 
GSTK1 
POLA1 
CDKN1A 
CDK6 
γ-Linolenate Biosynthesis II 
(Animals) 
 
FADS2 
 
ACSL3 
FADS2 
FADS1 
ACSL3 
 
 
Protein alterations were further evaluated with the analysis of the potential upstream 
regulator. The activation and inhibition of upstream regulators are determined by its 
activation and inhibition z-score, >2.0 or <-2.0. Based on the data set obtained, p53 
protein, nuclear factor (erythroid-derived 2)-like 2, and cyclin D1 proteins and these 
upstream regulators are important to predict the regulatory cascades involved with the 
related biological activities (Table 4.5). The activation scores showed that p53 protein 
and nuclear factor (erythroid-derived 2)-like 2 were activated while cyclin D1 protein 
was inhibited. 
 
 
Table 4.4 Continued 
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Figure 4.21: Differentially expressed proteins in A549 cells treated with helichrysetin for 6 hours, 24 hours, and 48 hours that were categorized based 
on its biological processes using Gene Ontology (GO) database searchers using R package, clusterProfiler (v. 3.0.5) and removing GO terms 
redundancy using GOSemSim (v.1.30.3). 
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Table 4.5: Upstream regulator analysis of differentially regulated proteins in A549 cells 
that are predicted to be activated and inhibited as determined by IPA. 
Upstream 
Regulator Molecule Type 
Predicted 
Activation 
State 
Activation  
z-score 
p-value of 
overlap 
p53 
transcription 
regulator Activated 2.404 3.13E-11 
NRF2 
transcription 
regulator Activated 2.776 1.39E-03 
Cyclin D1 
transcription 
regulator Inhibited -2.449 8.08E-05 
 
4.4.2 Validation of proteins related to DNA damage response, oxidative stress and 
cell cycle regulation pathways by Western blotting. 
A549 cells were treated with 15 µg/ml helichrysetin for 6 hours, 24 hours and 48 hours 
to investigate the expression of DNA damage response, oxidative stress and cell cycle 
related proteins. p21 protein, which is also known as cyclin-dependent kinase inhibitor 1 
(CDKN1A) was evaluated for its protein expression and there is an increase in the 
expression of p21 after treatment at 24 hours and 48 hours (6hr: 15.00; 24hr: 0.39; 48hr: 
0.52, Treated: 6hr: 0.91; 24hr: 0.50; 48hr: 1.13).  
The expression of heme-oxygenase 1 (HMOX1) was increased upon treatment with 
helichrysetin (6h: 1.00; 24hr: 1.30; 48hr: 1.19, Treated: 6hr: 1.23; 24hr: 1.80; 48hr: 
1.57). Nrf2 was investigated for its expression to validate result from the upstream 
regulator (6h: 1.00; 24hr: 0.95; 48hr: 1.11, Treated: 6hr: 0.92; 24hr: 1.23; 48hr: 0.62). 
Rb1 (6h: 1.00; 24hr: 1.02; 48hr: 0.66, Treated: 6hr: 0.97; 24hr: 0.50; 48hr: 0.56) and 
FANCD2 (6h: 1.00; 24hr: 0.64; 48hr: 0.67, Treated: 6hr: 0.15; 24hr: 0.49; 48hr: 0.15) 
proteins are the two proteins that are involved in the cell cycle progression and DNA 
repair and they are down-regulated after treatment with helichrysetin from 6 hours to 48 
hours. Studying the expression of ATM and BRCA1 proteins are important to 
understand its association with the expression of BRCA1-associated ATM activator in 
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ATM signaling pathway (Table 4.4). Results showed that BRCA1 (6h: 1.00; 24hr: 0.73; 
48hr: 0.46, Treated: 6hr: 1.10; 24hr: 0.50; 48hr: 0.47) was up-regulated at 6 hours 
treatment and subsequently reduced after 24 hours treatment while p-ATM (6h: 1.00; 
24hr: 0.87; 48hr: 0.68, Treated: 6hr: 0.80; 24hr: 0.64; 48hr: 0.72) was reduced after 
helichrysetin treatment. The expression of p53 tumor suppressor showed an increase 
after treatment with helichrysetin (6hr: 1.00; 24hr: 1.25; 48hr: 0.65, Treated: 6hr: 0.62; 
24hr: 0.57; 48hr: 1.51). Rad51 protein was up-regulated after 6 hours and 24 hours 
treatment and at 48 hours the expression was down-regulated (6hr: 1.00; 24hr: 1.01; 
48hr: 1.34, Treated: 6hr: 1.14; 24hr: 1.53; 48hr: 1.22).  
Cyclin D1, cyclin E, cyclin A and cyclin-dependent kinase 2 (cdk2) proteins are 
essential proteins in cell cycle regulation. Results showed that after treatment with 
helichrysetin, cyclin D1 protein showed increased expression after 6 hours treatment 
and subsequently decreased after 24 and 48 hours (6hr: 1.00; 24hr: 0.84; 48hr: 1.21, 
Treated: 6hr: 1.55; 24hr: 1.18; 48hr: 1.25). For cyclin E (6hr: 1.00; 24hr: 0.98; 48hr: 
1.14, Treated: 6hr: 0.71; 24hr: 0.60; 48hr: 0.72) and cyclin A (6h: 1.00; 24hr: 0.80; 48hr: 
0.72, Treated: 6hr: 0.75; 24hr: 0.72; 48hr: 0.55), the expression were down regulated 
after treatment with helichrysetin for 6 hours, 24 hours and 48 hours while cdk2 protein 
expression was down-regulated with helichrysetin treatment. (6hr: 1.00; 24hr: 0.64; 
48hr: 0.86, Treated: 6hr: 0.63; 24hr: 0.42; 48hr: 0.56). 
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Figure 4.22: Western blotting analysis. Effects of helichrysetin on A549 cells were 
evaluated by western blotting after treatment with 50 µM helichrysetin at 6, 24 and 48 
hours and without treatment (vehicle) at 6, 24 and 48 hours. 
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CHAPTER 5: DISCUSSION 
5.1 Helichrysetin inhibits growth of A549 cells and causes changes to the cell and 
nuclear morphology 
Based on the previous studies, helichrysetin showed effective anti-proliferative activity 
on human breast cancer cell line (6.5µM), human liver cancer cell line (51.1 µM) (Hua 
et al., 2008), human cervical cancer cell line (5.2 µM) (Vogel et al., 2008) and human 
fibrosarcoma cell line (40.1µM) (Ali et al., 2001) with active IC50 readings of 
approximately 50 µM and below.  
In this study, we reported the results of growth inhibitory activity of helichrysetin on 
five selected cell lines that include four human cancer cell lines and one human normal 
cell line. Helichrysetin has been proven to be active against A549 and Ca Ski cell lines 
with its highest inhibition on Ca Ski cells with IC50 of 14.52 ± 0.36 µg/ml and 8.88 ± 
0.13 µg/ml respectively. A compound that acts directly on cancer cells is considered 
effective when the IC50 range between 1-50 µM (Boik, 2001). Hence, helichrysetin has 
effective cytotoxicity on A549 and Ca Ski cell lines. 
Since this is the first finding of the action of helichrysetin on human lung cancer cells, 
the study further proceeds to focus on A549 cells. Time-course action of helichrysetin 
on A549 cell line is performed to understand its cytotoxicity at different time points. 
The time-dependent inhibition of helichrysetin on A549 cells showed that helichrysetin 
can inhibit the proliferation of cells up to 50% at 48 hours of treatment. The percentage 
of inhibition also increases in a time-dependent manner. This suggested that when cells 
are exposed to helichrysetin, the cell growth of the cells will be inhibited and this 
reflects the reduction in the cellular metabolic activity because MTT assay performs 
measurement of the cell population’s total mitochondrial activity related to its number 
of viable cells where the yellow tetrazolium salt, MTT will be cleaved to form soluble 
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blue formazan by the mitochondrial enzymes reflecting the activity of mitochondria in 
the cells (Sylvester, 2011).  
 
Figure 5.1: Cleavage of MTT to blue formazan product by mitochondrial reductase 
(Ebada et al., 2008) 
Result from the growth inhibitory assay revealed that helichrysetin can partially inhibit 
the mitochondrial activity in A549 cells (van Meerloo et al., 2011). IC50 reading for 
MRC-5, human lung fibroblast showed the highest value that is approximately 3 times 
higher than the active concentration, 50 µM showing that helichrysetin is not cytotoxic 
towards normal cells in comparison with cancer cells which prove it beneficial for the 
treatment of human lung cancer. 
The detection of unique morphological characteristics of cells upon stimulation by 
drugs or compounds is important in determining the mode of cell death occurred in the 
cells (Ziegler et al., 2004). Apoptotic treatments applied to cells can induce 
morphological alterations specific to the occurrence of apoptosis. Cells altered due to 
the occurrence of apoptosis exhibit shrinkage, rounding and blebbing of plasma 
membrane (Rello et al., 2005). Upon treatment of A549 cells with helichrysetin at 
increasing dosage, results showed that helichrysetin can cause the rounding and loss in 
volume/shrinkage of A549 cells under the microscope. A549 cells were found to be 
floating in the culture medium which implied that upon treatment with helichrysetin, the 
cells started to round up and losses its attachment from the surface of the culture 
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substratum. These are the morphological characteristics of cells that are specific to the 
occurrence of apoptosis (Gomez-Angelats et al., 2002; Marushige et al., 1998).  
Normally, uponstimulation of apoptosis, cells started to lose its contact with the 
neighboring cells in the early stage of apoptosis. Shrinkage of cells will lead to the 
formation of apoptotic bodies that contain cellular organelles, then engulfed by 
surrounding cells through phagocytosis (Hengartner, 2001). It has been shown in some 
studies that the apoptotic morphological changes are the results of proteases that cleave 
cell cytoskeleton proteins such as actin when cleaved will induce cellular shrinkage 
(Mashima et al., 1999). However, this action is insufficient to cause apoptotic cellular 
fragmentation. When apoptosis occurs, caspases cleave other proteins that are involved 
in the attachment, organization, maintenance of the cytoskeletons (Kothakota et al., 
1997). The induction of apoptotic cell morphology degeneration has also been observed 
in other studies related to natural compound (Koparal et al., 2003) such as studies on 
curcumin (Taraphdar et al., 2001), genistein (Qi et al., 2010), resveratrol (Clement et al., 
1998) and others. 
Nuclear morphological changes are very distinct and predominant in the process of 
apoptosis and the morphological hallmarks in nucleus are nuclear fragmentation and 
chromatin condensation (Ziegler et al., 2004). Observation from this study showed the 
effect of helichrysetin on nuclear morphology by fluorescence staining, DAPI stain and 
the result revealed that helichrysetin can induce chromatin condensation, subsequently 
the breaking of the condensed chromatin into nuclear fragments in A549 cells. These 
changes in the nuclear chromatin and the occurrence of nuclear fragmentation are the 
commonly recognized markers of apoptosis (Dini et al., 1996; Liu et al., 1998). DAPI 
stain is used commonly to stain by binding to the minor groove of double-stranded 
DNA, hence, suitable for the visualization of chromatin condensation and nuclear 
fragmentation (Chazotte, 2011).  
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Chromatin condensation usually occurs along the nuclear membrane forming crescent-
like structure and finally breaks up in the cells. Fragmented nuclear components 
eventually are packaged into apoptotic bodies at the final stage of apoptosis (Toné et al., 
2007). The phenomenon of the nuclear fragmentation in an intact cell is described as 
karyorhexis (Majno et al., 1995). Curcumin which is one of the major components in 
Curcuma longa rhizome a naturally derived phenolic component has also showed 
similar nuclear morphological changes as observed in this study (Lee et al., 2009).  
These changes in the nuclear morphology can be initiated by the cleavage activity of 
caspase 3 (Eidet et al., 2014). Caspase 3 can act by cleaving various proteins that are 
important to maintain the structural integrity of cell nuclei such as lamin and nuclear 
mitotic apparatus protein (NuMA). For chromatin condensation and the formation of 
apoptotic bodies to occur during the fragmentation of cell nuclei, the disintegration of 
nuclear matrix is required. NuMA and lamins served as the important markers for the 
structure of nuclear matrix (Merdes et al., 1996; Nickerson, 2001). Therefore, when 
apoptosis occurs and caspase 3 is initiated, it cleaves lamins and NuMA that supports 
the structure of cell nuclei and this will result in the occurrence of chromatin 
condensation and nuclear fragmentation following the initiation of apoptosis (Kivinen et 
al., 2005). 
The preliminary screening for the growth inhibitory effect of helichrysetin showed that 
helichrysetin can inhibit the growth of A549 cells in a time- and dose- dependent 
manner. Growth inhibition is the result of induction of cell death in A549 cells and this 
is characterized by the cellular and nuclear morphological changes in the cells observed 
by fluorescence and phase contrast microscopy. The features observed in the 
microscopy study showed apoptotic features, cell shrinkage, detachment, chromatin 
condensation and nuclear fragmentation in helichrysetin-treated A549 cells. Hence, 
helichrysetin has the ability to cause the occurrence of apoptotic features in the cells.  
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5.2 Helichrysetin can induce apoptosis features in A549 cells  
To further investigate the ability of helichrysetin to induce apoptosis in A549 cells, 
further study using the flow cytometry to observe biochemical hallmarks of apoptosis 
and cell cycle, and western blotting to understand the mechanisms of apoptosis have 
been performed. Results from this study showed that helichrysetin displayed time- and 
dose- dependent effect on A549 cells in most of the detection of biochemical hallmarks 
of apoptosis. 
Firstly, the induction of apoptosis was detected by the changes in the plasma membrane 
integrity in A549 cells upon treatment with helichrysetin at increasing concentrations 
and time points. In the Annexin V-FITC/PI detection, Annexin V binds to 
phosphatidylserine that is translocated to the outer leaflet of cell membrane during the 
early stage of apoptosis (Martin et al., 1995). The percentage of Annexin V-positive 
cells that increases in both the time- and dose- dependent study showed that 
helichrysetin is capable of inducing apoptosis signify by the disruption of the cell 
membrane integrity hence the loss of membrane asymmetry (Fadok et al., 1992). The 
changes in the composition of the cell membrane through this process will serve as a 
signal for phagocytes to recognize dying cells for the clearance of apoptotic cells (Erwig 
et al., 2007).  
Treatment with helichrysetin also caused the release of cytochrome c into the cytosol 
from mitochondria. Hence, the effect of helichrysetin on mitochondrial membrane 
potential was determined using JC-1, a mitochondrial-specific cationic dye which will 
measure the loss of mitochondrial membrane potential (Perry et al., 2011). In untreated 
cells, most A549 cells exhibit red fluorescence due to the formation of J-aggregates 
indicating the presence of more cells with intact mitochondrial membrane potential 
while the disruption of mitochondrial membrane potential occurred in treated cells 
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showed by the accumulation of JC-1 dye in the cytoplasm in the monomeric form with 
higher green fluorescence (Smiley et al., 1991).  
Exposure of A549 cells with helichrysetin caused the loss of mitochondrial membrane 
potential in a dose- and time- dependent manner. The release of cytochrome c started as 
an early event after the exposure of the cells to helichrysetin at 6 hours treatment. 
Because of the cytochrome c release into the cytoplasm, it may involve the opening of 
permeability transition pore of the mitochondrial inner membrane which caused the 
collapse in the mitochondrial membrane potential (Vander Heiden et al., 1997). 
Opening of the pore also result in swelling of the mitochondria. Disruption and swelling 
of the mitochondrial have been described as events that occur during apoptosis when 
tumor cells are exposed to cancer chemopreventive agents (Nakamura et al., 2002).  
TUNEL assay was performed to detect apoptotic cells with fragmented DNA. DNA will 
be cleaved by the nucleases during the process of apoptosis resulting in the exposure of 
3´OH that serves as a site for Br-dUTP nick labeling (Darzynkiewicz et al., 2008).  
As A549 cells were treated with helichrysetin, there is an increase in the percentage of 
cells in the apoptotic cells region indicating the increase of DNA fragmentation in the 
cells. Higher concentrations of helichrysetin and longer exposure resulted in the higher 
number of free DNA ends that are labeled with TUNEL assay (Jakob et al., 2011). This 
indicates that helichrysetin can cause the production of more DNA double strand breaks 
in the cells. DNA double strand breaks are one of the most severe forms of DNA 
damage and the failure of the DNA repair system will trigger apoptotic responses 
through the activation of mitochondrial intrinsic pathway (Kaina, 2003). 
Cell cycle analysis showed that the increase in helichrysetin treatment caused the 
elevation in the percentage of cells in S phase of cell cycle. The accumulation of cells in 
S phase increased significantly at concentration of 15 µg/ml to 20 µg/ml and this may 
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contribute to the initiation of cell death in A549 cells. The effect of helichrysetin on cell 
cycle progression with S phase arrest is distinct only at high dosage, 15 µg/ml to 20 
µg/ml.  
Cell cycle arrest that occurs in the S phase can be due to the accumulation of DNA 
strand breaks in the cells (Wyllie et al., 1996). This is to prevent the damaged DNA to 
proceed further into the next phase of the cell cycle that will finally produce cells that 
have defective DNA. DNA damage response can be triggered at this stage to initiate 
DNA repair.  
The progression of S phase in cell cycle is supported by the cell cycle related proteins, 
cyclin A, cyclin E, CDK2, and CDC25A (Collins et al., 1997) and it has been shown in 
some studies that the inhibition of these proteins will lead to S phase arrest (Hung et al., 
2013). When cell cycle failed to progress through S phase, this will trigger the 
occurrence of apoptosis in A549 cells. 
Flow cytometry studies have proven that helichrysetin can trigger apoptosis in A549 
cells. Understanding the molecular mechanisms of action of helichrysetin that trigger 
cell death in A549 cells is important to develop potential therapeutic strategy. Hence, 
the protein expression of apoptotic related proteins was investigated to better understand 
the proteins that are involved in the action of helichrysetin.  
Caspases are a group of cysteine proteases that are important in the process of apoptosis. 
Based on the observations from this study, helichrysetin served as the stimuli for the 
activation of caspase 3, 8 and 9. Exposure of A549 cells to helichrysetin resulted in the 
increase of cleaved caspase 3 proteins and decrease of pro-caspase 3. Caspase 3 is 
activated by the cleavage of pro-caspase 3 into cleaved caspase 3 by initiator caspase or 
other proteases under certain circumstances (Boatright et al., 2003). Activation of 
caspase 3 catalyzes the cleavage of proteins involved in cell death such as 
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retinoblastoma (Rb) protein, poly (ADP-ribose) polymerase (PARP), and DNA-
dependent protein kinase catalytic subunit (DNA-PKcs) to induce apoptosis in the cells 
(Janicke et al., 1998). 
Caspase 8 and caspase 9 are both initiator caspases that play important roles in the 
initiation of extrinsic and intrinsic apoptotic pathways respectively. Results showed that 
both pro-caspase 8 and pro-caspase 9 are activated upon exposure to helichrysetin 
displayed by the increase in the cleaved-form protein expression of both caspases. The 
intrinsic pathway of apoptosis is activated upon the cleavage of caspase 9 following the 
treatment by helichrysetin. This matches the result where cytochrome c is shown to be 
released into the cytosol from the mitochondria which lead to the activation of caspase 9. 
This activation is reported to occur in a complex called the apoptosome (Zou et al., 
1999). Apoptosome will then proceed to activate pro-caspase 3 by its proteolytic 
activity and finally cause the execution of apoptosis (Würstle et al., 2012). 
Activation of caspase 8 is induced by the signaling by death-inducing signaling complex 
(DISC) where death receptors are involved (Medema et al., 1997). Caspase 8 
subsequently induces the activation of downstream effector proteins caspase 3 and 
caspase 7 for the occurrence of apoptosis in the cells (Hirata et al., 1998). It’s been 
reported that caspase 8 can also induce mitochondrial activated apoptosis by cleaving 
Bcl2-interacting protein (BID) which cause the translocation of BID to the mitochondria 
hence inducing the release of cytochrome c into the cytosol (Luo et al., 1998).  
As a result of caspase 3 activation, PARP will be deactivated by the cleavage activity 
catalyzed by caspase 3 (Tewari et al., 1995). It can be observed in the results that there 
is an increase expression of cleaved PARP upon treatment with helichrysetin while full 
length PARP showed down regulation. This proved that helichrysetin triggered the 
downstream apoptotic pathways deactivating PARP for the execution of apoptosis in 
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A549 cells. Caspase 3 cleaved PARP to produce N-terminal DNA-binding domain and 
C-terminal catalytic fragment followed by the DNA repair blockage of N-terminal 
DNA-binding domain to promote the occurrence of apoptosis (D'Amours et al., 2001). 
Study has demonstrated that helichrysetin can cause changes to Bcl-2 family proteins in 
A549 cells. After treatment with helichrysetin at different exposure time, the expression 
of Bax protein showed increment at 6, 24, and 48 hours treatment while Bcl-2 protein 
was reduced through these time points. This indicates helichrysetin can elevate the pro-
apoptotic proteins in A549 cells, sensitizing the cells to apoptosis given the fact that 
Bcl-2 family proteins are primary regulator of apoptosis (Siddiqui et al., 2015). Bcl-2 
protein is found to inhibit cell death by preserving the integrity of mitochondrial 
membrane as the hydrophobic carboxyl-terminal domain of this protein is linked to the 
outer membrane of mitochondria. Bcl-2 prevents the oligomerization of Bax/Bak 
proteins that will cause the release of apoptogenic substances from mitochondria (Tzifi 
et al., 2012). Hence, the inhibition of Bcl-2 can initiate the activation of Bax and finally 
apoptosis process. 
When apoptosis is initiated, Bax will move from the cytosol to the membrane of 
mitochondrial to form mitochondrial outer membrane permeabilization (MOMP) 
complex, hence, triggering the critical apoptotic caspase cascade (Green et al., 2004). 
When Bax intergrates with mitochondria, it will oligomerizes with Bak to cause the 
release of cytochrome c (Petros et al., 2004). During the activation of Bax, some studies 
have proven that Bax will undergo conformational rearrangements to be associated with 
the mitochondrial membrane (Westphal et al., 2011). 
Hence, the exposure of A549 cells to helichrysetin induces apoptosis in the cells 
detected by flow cytometry that showed biochemical hallmark of apoptosis such as loss 
of membrane asymmetry, DNA fragmentation, and disruption of mitochondrial 
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membrane potential. Helichrysetin induces the up-regulation of upstream and 
downstream pro-apoptotic proteins related to the mitochondrial-mediated apoptosis 
while the anti-apoptotic proteins were diminished upon treatment with helichrysetin. 
5.3 Proteomic study to investigate the mechanism of action of helichrysetin on 
A549 cells  
The mechanism underlying helichrysetin growth inhibitory activity against A549 cells 
has not been studied and this study provided the proteomics profiling results to find the 
differentially expressed proteins in A549 cells. To compare the proteome changes from 
untreated A549 cells versus 6 hours, 24 hours and 48 hours treated cells, proteins with 
95% confidence level with z score >2.0 or <-2.0 were chosen as differentially regulated 
proteins.  
Ingenuity Pathway Analysis (IPA) software was used to investigate the significantly 
altered pathways and activated upstream regulator. The top 10 significantly altered 
pathways are shown in the Figure 4.20. Of these canonical pathways, proteins that are 
highly regulated in the pathways, cell cycle: G2/M DNA damage checkpoint regulation, 
NRF2-mediated oxidative stress response, ATM signaling, and hereditary breast cancer 
signaling are the focus in this study for further elaboration on the mechanisms of action 
of helichrysetin in A549 cells. These pathways might contribute to the mechanisms of 
cell death in helichrysetin-treated A549 cells. 
The proteomic study showed that this compound impaired the growth of A549 cancer 
cells by altering its DNA damage response, cell cycle regulation and inducing oxidative 
stress in the cells. p21 protein which is highly expressed in the cells upon treatment with 
helichrysetin plays an important role in inhibiting the activity of cyclin-CDKs 
complexes. p21 protein plays an important role in the growth arrest upon DNA damage 
and its overexpression can promote G1 and G2 or S-phase cell cycle arrest through the 
binding of p21 protein to CDKs in response to stimuli (Abbas et al., 2009).  
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By inhibiting CDKs and cyclins, p21 reduces the expression of both types of proteins. 
Besides, p21 also contains a carboxyl terminal binding site that matches PCNA that 
plays essential role in DNA replication and DNA repair including nucleotide excision 
repair, base excision repair and mismatch repair. The interaction of p21 with PCNA will 
block DNA synthesis facilitated by DNA polymerase δ (Waga et al., 1994). p21 is 
largely regulated by p53 the transcriptional level since one of its two p53 binding sites 
is responsive to p53 upon DNA damage (El-Deiry et al., 1995). With the help of p53, 
tumor suppressor protein, it will lead to the induction of both apoptosis and cell cycle 
arrest (Giono et al., 2006).  
In conjunction with results from the activated upstream regulator from IPA analysis, 
p53 is one of the regulators activated with Z-score 2.404 and its expression is further 
proven with western blotting (Figure 4.22). p53 protein can be activated and stabilized 
in processes such as DNA damage, hypoxia, DNA repair, apoptosis and others in the 
presence of DNA-damaging agents, chemotherapeutic drugs, and irradiation (Giaccia et 
al., 1998). This happens when there is a phosphorylation of its transactivation domain, 
and acetylation and phosphorylation of its basic allosteric control region. The two 
important kinases involved in the activation of p53 are ATM and ATR (ATM related) 
kinases.  
Result from western blot showed that p53 is highly expressed in the early exposure of 
helichrysetin late at 48 hours which is similar to the expression of p21 protein. It has 
been reported that upon DNA damage, p53 the upstream regulator induces p21 
expression which then localized to nucleus for cell cycle arrest (El-Deiry et al., 1994). 
Besides, p53 also regulates the expression of apoptotic proteins such as Bcl-2 and TNF 
receptor families. The first apoptotic protein that is associated with p53 activation is 
Bax pro-apoptotic protein that contains BH3-domain and p53 also represses Bcl-2 
which contributes to the blocking of survival signals (Miyashita et al., 1994). 
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ATM signaling is one of the top canonical pathways affected by the treatment of 
helichrysetin. This signaling pathway is involved in the cellular DNA damage response 
pathway and ATM, ataxia-telangiectasia mutated protein is a protein kinase that 
mediates responses to DNA double strand breaks in the cells (Kitagawa et al., 2005). 
BRCA1-associated ATM activator (BAAT) is responsible for the activation of ATM 
kinase that stimulate the DNA damage repair and regulate cell cycle checkpoints in cells 
(Minami et al., 2014).  
Observation from the quantitative proteomic study showed that BAAT was down-
regulated upon treatment with helichrysetin in comparison to its untreated control. The 
reduction in the expression of BAAT is also coupled with the western blotting results 
that show the reduction in the protein expression of BRCA1 protein and phospho-ATM 
at the given time points. ATM signals with MRN complex from DNA double strand 
breaks (DSBs) and activates the DNA damage checkpoint in the cells. ATM 
autophosphorylation has become an important readout for the activation of ATM. 
Therefore, the low expression of p-ATM in A549 cells treated with helichrysetin 
indicate that helichrysetin lowers the activation of ATM that is important for the 
stimulation of DNA damage repair subsequently causing the failure of DNA damage 
repair in A549 cells.  
Fanconi’s anemia (FA) is a genetic disorder characterized by its chromosomal 
instability, susceptibility to cancer, and hypersensitivity to DNA cross-linking agents. 
FA proteins form complexes that are important for the activation of FANCD2 that acts 
together with BRCA1 and BRCA2 proteins in DNA damage response (Garcia-Higuera 
et al., 2001). When DNA damage occurs, it activates the FA complex-dependent 
monoubiquitination of the FANCD2. FANCD2 protein plays a pivotal role in 
coordinating S phase in cell cycle and DNA double strand breaks repair (Ho et al., 
2006).  
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The monoubiquitination of FANCD2 results in the relocation of FANCD2 from a 
nuclear compartment to S-phase-specific foci that contains Rad51, BRCA1 and other 
proteins related to DNA repair to facilitate repair of DNA in S phase of cell cycle 
(Taniguchi et al., 2002). FANCD2 and Rad51 complexes are involved in DNA repair by 
homologous recombination. However, FANCD2 protein is down-regulated upon 
treatment of helichrysetin in A549 cells. Hence, FANCD2 monoubiquitination will be 
disrupted and the DNA repair is diminished upon treatment with helichrysetin resulting 
in the presence of irreparable DNA in the cells. Damaged DNA that is failed to be 
repaired will cause cell cycle arrest and finally triggering the process of apoptosis in 
A549 cells. 
In relation to the hereditary breast cancer signaling, retinoblastoma 1 (Rb1) is also one 
of the proteins affected by the treatment of helichrysetin. In this quantitative proteomic 
study, it is shown that expression of Rb1 protein is down-regulated upon treatment with 
helichrysetin in a time-dependent manner. Rb1 protein plays an important role in the 
DNA double-strand break (DSB) repair which will cause genetic instability (Manning et 
al., 2012). Non-homologous end joining is a mechanism where DNA double strand 
breaks are repaired during G1 and S phase of cell cycle (Huang et al., 2016). Since Rb1 
protein is important in the DNA repair mechanism, the loss of Rb1 protein upon 
treatment with helichrysetin impairs the DNA repair in the cells. Inability of the cells to 
repair DSBs causes severe DNA damage and eventually cell death (Cook et al., 2015). 
When cells are exposed to DNA-damaging agents, RAD51 will increase in the nucleus. 
RAD51 is an important component of homologous recombination and it is recruited to 
the DNA break sites and bind to the single-stranded DNA break and then DNA will be 
repaired by DNA strand exchange with homologous chromosome for recovery of 
missing genes (Gildemeister et al., 2009).  
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Upon treatment with helichrysetin, the expression of RAD51 protein increases at 6 
hours and 24 hours treatment and decreases after 48 hours exposure to helichrysetin. In 
relation to ATM kinase and BRCA1 protein, ATM will phosphorylate BRCA1 and c-
ABL tyrosine kinase and subsequently phosphorylates RAD51 to form RAD51 repair 
protein complex following DNA damage (Chen et al., 1999). BRCA1 regulates RAD51 
function upon DNA damage which is required for RAD51-mediated homologous 
recombination (Cousineau et al., 2005). Therefore, RAD51 might have been trigger in 
the early stage of the treatment for DNA repair but due to the lack of BRCA1 and ATM 
to facilitate the DNA repair, the mechanism might have failed too. 
As observed in the results from the top canonical pathway from IPA, NRF2-mediated 
oxidative stress response was activated in A549 cells treated with helichrysetin. Heme-
oxygenase 1 (HMOX1) is one of the antioxidant protective enzymes that are being up-
regulated by helichrysetin in A549 cells which is due to the production of reactive 
oxygen species (ROS) in the mitochondria and endoplasmic reticulum of cells. The 
increase of HMOX1 could be a result of oxidative stress through the activation of 
Keap1 ubiquitination-degradation. During this process, there is a movement of Nrf2 
transcription factor into the nucleus that stimulates HMOX1 (Gozzelino et al., 2010). 
The transactivation of HMOX1 is regulated by the binding of NRF2 transcription factor 
to antioxidant response element (ARE) (Reichard et al., 2007). The result from the IPA 
analysis on the upstream regulator shows that helichrysetin trigger the activation of 
NRF2 transcription factor and this is further validated using western blotting in Figure 
4.22. Results showed that NRF2 and HMOX1 proteins were up regulated and this is 
highly related to the presence of ROS in A549 cells which can result in the induction of 
apoptosis (Huang et al., 2003).  
Thus, the results from the proteomic study and western blotting showed that 
helichrysetin might be able to induce the production of reactive oxygen species in A549 
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cells. The production of reactive oxygen species is indicated by the stimulation of the 
antioxidant responses, NRF2 the master regulator and HMOX1 the antioxidant enzyme. 
The presence reactive oxygen species in the cells will cause the occurrence of DNA 
damage in A549 cells.  
However, due to inhibitory activity of helichrysetin, DNA damage repair mechanism 
was repressed which can be observed by the down-regulation of ATM kinase, BRCA1, 
BAAT, Rb1 protein, and FANCD2. Tumor suppressor protein, p53 and p21, the 
inhibitor of cyclin-dependent kinase were elevated upon treatment with helichrysetin in 
A549 cells which imply the deregulation of cell cycle and the occurrence of S phase cell 
cycle arrest. Excessive damage to the DNA caused the occurrence of cell cycle arrest 
and eventually stimulated the mechanism of apoptosis in A549 cells.  
 
 
Figure 5.2: Illustration of the molecular mechanisms of action by helichrysetin on A549 
cells. Helichrysetin caused oxidative stress in the cells that induce DNA damage, and 
this compound inhibits DNA damage response that leads to cell cycle arrest and 
subsequently stimulation of apoptosis in A549 cells. Pathway illustration is drawn using 
IPA software. 
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CHAPTER 6: CONCLUSION 
In this thesis, helichrysetin a naturally occurring chalcone has been investigated for its 
growth inhibitory activity on four selected cancer cell lines and it is proven to be 
effective on human cervical carcinoma cell line, Ca Ski and human lung 
adenocarcinoma cell line, A549 with IC50 of 31.02±0.45 µM and 50.72±1.26 µM 
respectively. Since this is the first discovery on the activity of helichrysetin on human 
lung cancer, further investigations have been done on A549 cancer cells. 
Helichrysetin is able to induce apoptotic morphological changes in A549 cells. This is 
indicated by the decrease in cell volume, cell rounding and the loss of cells support to 
the culture substratum. Helichrysetin also induces the changes in nuclear morphology 
shown by the occurrence of chromatin condensation and nuclear fragmentation in the 
cells. Flow cytometry studies have revealed that this compound can induce apoptosis in 
A549 cells defined by the changes in biochemical characteristics in the cells such as the 
externalization of phosphatidylserine, internucleosomal DNA fragmentation, collapse of 
the mitochondrial membrane potential and cell cycle arrest at the S phase. Helichrysetin 
also triggered the mitochondrial-mediated apoptotic pathway through the activation of 
caspase 3,8,9 and the cleavage of PARP. Cytochrome c which is a marker of apoptosis 
also found to be up-regulated in the helichrysetin-treated A549 cells. Changes in the 
expression of Bcl-2 family proteins, the major regulator of apoptosis can also be 
observed. Pro-apoptotic protein, Bax has been activated while the anti-apoptotic protein 
has been deactivated upon treatment with helichrysetin. 
Proteomic studies further revealed the mechanisms involved in the induction of 
apoptosis in A549 cells in effect of helichrysetin treatment. It is shown that 
helichrysetin induces the antioxidant protective proteins, Nrf2 and HMOX1 that are 
commonly activated upon the production of ROS in the cells. This observation 
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suggested the production of ROS in the cells that might have contributed to the DNA 
damage in the cells which eventually leads to cell cycle arrest.  
Cell cycle arrest functions as a process to allow for the repairing of damaged DNA in 
the cells. When DNA damage occurs in the cells, DNA damage response is responsible 
to trigger the signaling cascades to repair damaged DNA. This study showed that DNA 
damage response has been suppressed in A549 cells upon exposure to helichrysetin and 
this prevents the cells from undergoing DNA damage repair. The failure in the DNA 
damage repair will lead the cells into undergoing cell death and in this case, apoptotic 
cell death. Cells that possess the damaged DNA were arrested in the S phase of cell 
cycle to facilitate DNA repair. When excessive DNA damage was present in A549 cells, 
apoptosis was triggered in the cells to facilitate cell suicide. 
Therefore, the finding of this study on the activity and the mechanism of action of 
helichrysetin on human lung adenocarcinoma cell, A549, provides an insight on the 
effective anti-cancer activity of helichrysetin on human lung cancer cells through its 
ability to cause changes to the process of DNA damage response in human lung cancer. 
The finding of the mechanism of action from this study will provide an opportunity for 
the development of helichrysetin as cancer therapeutic by targeting the DNA damage 
response elements specifically in lung cancer cells. Hence, the future direction of this 
research should include the genetic modification of the targeted genes related to the 
DNA damage response for further confirmation on the mechanism of action of 
helichrysetin in A549 cells. Future studies should also include the investigation of other 
types of human cancer cell line to broaden the understanding on the effect of 
helichrysetin on human malignancies.  
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APPENDIX 
APPENDIX A-Differentially expressed proteins at 6 hours helichrysetin treatment 
Accession Description 
log2 protein 
ratio 
protein ratio 
Z score Gene name 
Coverage 
Matched 
peptides 
Unique 
peptides 
MW 
[kDa] 
calc. pI 
P62258 14-3-3 protein epsilon  0.499 1.413 2.226 YWHAE 69.02% 16 13 29.2 4.74 
P61981 14-3-3 protein gamma 0.454 1.370 2.023 YWHAG 68.83% 15 10 28.3 4.89 
P31947 14-3-3 protein sigma 0.465 1.381 2.075 SFN 63.71% 15 11 27.8 4.74 
C9JYQ9 
60S ribosomal protein L22-like 
1 -0.527 0.694 -2.399 RPL22L1 
35.54% 
3 3 
14.5 9.38 
Q8N3C0 
Activating signal cointegrator 1 
complex subunit 3 -0.475 0.720 -2.164 ASCC3 
5.77% 
9 9 
251.3 7.09 
Q59EC0 
Adenosine deaminase, RNA-
specific isoform ADAR-a  -0.448 0.733 -2.043 N/A 
21.86% 
23 23 
137.7 8.48 
P12235 ADP/ATP translocase 1  0.510 1.424 2.276 SLC25A4 53.02% 15 2 33 9.76 
P12236 ADP/ATP translocase 3 0.755 1.688 3.383 SLC25A6 56.04% 17 2 32.8 9.74 
P54920 
Alpha-soluble NSF attachment 
protein  0.602 1.518 2.692 NAPA 
58.64% 
13 12 
33.2 5.36 
A0A024R3N3 
Amyloid beta (A4)-like protein 
2, isoform CRA_a  0.543 1.458 2.428 APLP2 9.72% 6 5 
81.9 4.81 
P04083 Annexin A1 O 0.473 1.388 2.110 ANXA1 65.03% 20 20 38.7 7.02 
P07355 Annexin A2  1.446 2.725 6.498 ANXA2 64.90% 23 23 38.6 7.75 
P09525 Annexin A4  0.471 1.387 2.103 ANXA4 66.46% 23 22 35.9 6.13 
P08758 Annexin A5  0.522 1.436 2.331 ANXA5 63.44% 18 17 35.9 5.05 
Q15121 
Astrocytic phosphoprotein 
PEA-15  0.551 1.466 2.463 PEA15 
42.31% 
4 4 
15 5.02 
F1T0L5 
ATP-dependent RNA helicase 
DDX51  -0.432 0.741 -1.972 DDX51 
13.51% 
6 6 
72.4 8.16 
Q8TDD1 
ATP-dependent RNA helicase 
DDX54  -0.959 0.515 -4.345 DDX54 
9.65% 
7 6 
98.5 10.02 
O95817 
BAG family molecular 
chaperone regulator 3 0.862 1.818 3.865 BAG3 
35.30% 
15 15 
61.6 6.95 
O75531 Barrier-to-autointegration factor 0.536 1.450 2.392 BANF1 66.29% 6 6 10.1 6.09 
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Q6PJG6 
BRCA1-associated ATM 
activator 1  -1.565 0.338 -7.078 BRAT1 
6.21% 
4 4 
88.1 5.27 
Q9NZZ3 
Charged multivesicular body 
protein 5  0.446 1.363 1.989 CHMP5 
17.81% 
3 3 
24.6 4.83 
K7EIG1 
Clustered mitochondria protein 
homolog  0.456 1.372 2.034 CLUH 
27.90% 
29 1 
140.5 6.4 
P38432 Coilin  -0.547 0.685 -2.488 COIL 6.77% 3 3 62.6 9.07 
F8VXD2 Cyclin-dependent kinase 4 -0.633 0.645 -2.875 CDK4 25.76% 3 2 14.9 5.85 
B3GQE6 DEAD box polypeptide 27  -0.593 0.663 -2.696 DDX27 6.01% 5 5 86.6 9.25 
P15924 Desmoplakin -1.020 0.493 -4.623 DSP 4.25% 11 10 331.6 6.81 
Q2NKX8 
DNA excision repair protein 
ERCC-6-like  -0.461 0.727 -2.101 ERCC6L 
6.48% 
6 6 
141 5.31 
P25685 
DnaJ homolog subfamily B 
member 1 0.801 1.743 3.589 DNAJB1 
46.18% 
16 15 
38 8.63 
Q9UDY4 
DnaJ homolog subfamily B 
member 4  0.513 1.427 2.290 DNAJB4 
28.78% 
8 6 
37.8 8.5 
Q9BXW9 
Fanconi anemia group D2 
protein  -0.890 0.540 -4.037 FANCD2 
1.52% 
2 2 
164 5.88 
O95864 Fatty acid desaturase 2 -0.890 0.540 -4.037 FADS2 11.04% 5 5 52.2 8.82 
P02792 Ferritin light chain  1.064 2.090 4.772 FTL 44.00% 7 7 20 5.78 
Q9BQS8 
FYVE and coiled-coil domain-
containing protein 1  -0.499 0.708 -2.273 FYCO1 
2.44% 
3 3 
166.9 4.92 
E9PG40 
Gamma-secretase C-terminal 
fragment 59  0.631 1.549 2.824 APP 
17.51% 
10 9 
80.8 4.82 
A0A0G2JPW5 
Gamma-tubulin complex 
component 5 -1.122 0.460 -5.081 TUBGCP5 
2.44% 
2 2 
118.3 5.94 
Q9Y5Q9 
General transcription factor 3C 
polypeptide 3  -0.798 0.575 -3.622 GTF3C3 
9.48% 
6 6 
101.2 5.07 
Q5T7U1 
General transcription factor 3C 
polypeptide 5  -0.527 0.694 -2.399 GTF3C5 
10.07% 
3 3 
52.3 6.37 
P09211 Glutathione S-transferase P  0.463 1.378 2.063 GSTP1 60.95% 11 8 23.3 5.64 
Q8N4P8 GTPBP4 protein -0.468 0.723 -2.132 GTPBP4 28.80% 13 13 73.7 9.55 
A0A024R2Z6 
Guanine nucleotide binding 
protein-like 3  -0.470 0.722 -2.141 GNL3 
17.13% 
10 9 
60.5 8.79 
Q9HBB9 HC56  -0.446 0.734 -2.034 N/A 10.51% 9 8 118.7 6.14 
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Q6AI08 
HEAT repeat-containing 
protein 6  -0.606 0.657 -2.755 HEATR6 
7.03% 
5 5 
128.7 7.03 
P08107;P0DMV8 
Heat shock 70 kDa protein 
1A/1B  1.389 2.619 6.239 HSPA1A 
64.59% 
34 22 
70 5.66 
Q92598 Heat shock protein 105 kDa 0.504 1.418 2.249 HSPH1 64.92% 45 41 96.8 5.39 
P09601 Heme oxygenase 1  1.631 3.098 7.331 HMOX1 46.53% 10 10 32.8 8.25 
Q96KK5 Histone H2A type 1-H  0.842 1.793 3.775 HIST1H2AH 27.34% 3 2 13.9 10.89 
A8K9J7 Histone H2B 0.859 1.814 3.851 N/A 40.48% 5 5 14 10.32 
P62805 Histone H4 0.831 1.780 3.726 HIST1H4A 45.63% 5 5 11.4 11.36 
P08243-2 
Isoform 2 of Asparagine 
synthetase [glutamine-
hydrolyzing]  0.458 1.374 2.042 ASNS 
42.78% 
17 17 
62.1 7.06 
Q96SZ6-2 
Isoform 2 of CDK5 regulatory 
subunit-associated protein 1  -0.675 0.627 -3.064 CDK5RAP1 
4.63% 
3 3 
56.2 7.94 
P14635-2 
Isoform 2 of G2/mitotic-
specific cyclin-B1  0.528 1.442 2.356 CCNB1 
11.62% 
4 4 
44.1 7.37 
Q12789-3 
Isoform 2 of General 
transcription factor 3C 
polypeptide 1  -0.761 0.590 -3.455 GTF3C1 
7.10% 
11 10 
236.1 7.52 
Q96CP6-2 
Isoform 2 of GRAM domain-
containing protein 1A  -0.507 0.704 -2.310 GRAMD1A 
12.06% 
7 7 
79.3 6.67 
Q5TA45-2 
Isoform 2 of Integrator complex 
subunit 11  -0.682 0.624 -3.095 CPSF3L 
8.82% 
3 3 
56 8.32 
Q6KB66-2 
Isoform 2 of Keratin, type II 
cytoskeletal 80  -0.777 0.584 -3.527 KRT80 
13.98% 
5 4 
47.2 5.3 
P01130-2 
Isoform 2 of Low-density 
lipoprotein receptor 0.575 1.490 2.571 LDLR 
4.40% 
3 3 
75.8 5.21 
O15091-2 
Isoform 2 of Mitochondrial 
ribonuclease P protein 3  -0.612 0.655 -2.780 KIAA0391 
11.46% 
6 6 
65.4 8.5 
Q6T4R5-2 
Isoform 2 of Nance-Horan 
syndrome protein  -0.932 0.524 -4.226 NHS 
1.60% 
2 2 
176.6 6.79 
Q9NVV4-2 
Isoform 2 of Poly(A) RNA 
polymerase -0.513 0.701 -2.333 MTPAP 
8.43% 
5 4 
78.8 8.28 
Q9UNS1-2 
Isoform 2 of Protein timeless 
homolog  -1.304 0.405 -5.902 TIMELESS 
4.14% 
4 4 
138.4 5.38 
Q7L7V1-2 
Isoform 2 of Putative pre-
mRNA-splicing factor ATP- -0.575 0.672 -2.613 DHX32 
6.50% 
3 3 
75 4.91 
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dependent RNA helicase 
DHX32  
P10586-2 
Isoform 2 of Receptor-type 
tyrosine-protein phosphatase F  -0.557 0.680 -2.536 PTPRF 
4.06% 
6 6 
211.6 6.42 
P10599-2 Isoform 2 of Thioredoxin 0.522 1.436 2.329 TXN 67.06% 6 6 9.4 6.04 
O95218-2 
Isoform 2 of Zinc finger Ran-
binding domain-containing 
protein 2  0.614 1.531 2.748 ZRANB2 
24.06% 
7 7 
36.3 9.76 
Q07973-3 
Isoform 3 of 1,25-
dihydroxyvitamin D(3) 24-
hydroxylase -1.138 0.455 -5.152 CYP24A1 
9.14% 
3 3 
43 7.4 
Q9Y4W2-3 
Isoform 3 of Ribosomal 
biogenesis protein LAS1L  -0.612 0.655 -2.780 LAS1L 
5.04% 
3 3 
76.8 4.68 
Q6YHU6-3 
Isoform 3 of Thyroid adenoma-
associated protein  -0.889 0.540 -4.031 THADA 
2.39% 
3 3 
211 6.1 
P10909-4 Isoform 4 of Clusterin 0.787 1.726 3.526 CLU 11.30% 4 4 48.8 6.71 
P53355-4 
Isoform 4 of Death-associated 
protein kinase 1 -0.645 0.640 -2.931 DAPK1 
6.67% 
7 6 
152.4 7.17 
Q15185-4 
Isoform 4 of Prostaglandin E 
synthase 3  0.442 1.359 1.970 PTGES3 
47.48% 
6 6 
16.5 4.81 
Q9BV36-5 Isoform 5 of Melanophilin  -0.536 0.690 -2.441 MLPH 7.88% 3 2 50.7 6.19 
Q5GLZ8-6 
Isoform 6 of Probable E3 
ubiquitin-protein ligase HERC4  -0.623 0.650 -2.830 HERC4 
15.42% 
10 10 
106.6 6.47 
Q13907 
Isopentenyl-diphosphate Delta-
isomerase 1 0.770 1.705 3.448 IDI1 
32.16% 
6 6 
26.3 6.34 
H6VRF8 Keratin 1  0.551 1.466 2.463 KRT1 43.01% 30 24 66 8.12 
P13645 Keratin, type I cytoskeletal 10  0.544 1.459 2.432 KRT10 39.21% 21 18 58.8 5.21 
P08779 Keratin, type I cytoskeletal 16  -0.457 0.729 -2.083 KRT16 21.99% 12 3 51.2 5.05 
A0A087X106 Keratin, type II cuticular Hb1  -1.604 0.329 -7.254 KRT81 25.21% 12 12 53.1 5.47 
P35908 
Keratin, type II cytoskeletal 2 
epidermal  0.498 1.412 2.221 KRT2 
46.01% 
25 17 
65.4 8 
P20700 Lamin-B1  -0.921 0.528 -4.177 LMNB1 24.06% 14 12 66.4 5.16 
Q03252 Lamin-B2  -0.822 0.566 -3.731 LMNB2 7.83% 5 3 67.6 5.35 
E9PP40 
Leucine-rich repeat-containing 
protein 14 -1.214 0.431 -5.497 LRRC14 
14.95% 
3 3 
33.5 8.31 
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A0A087X0S7 
Leucine-rich repeat-containing 
protein 41 -1.370 0.387 -6.198 LRRC41 
6.14% 
2 2 
56.4 8.73 
Q96BZ8 
Leukocyte receptor cluster 
member 1 0.522 1.436 2.331 LENG1 
22.35% 
4 3 
30.5 9.69 
P14174 
Macrophage migration 
inhibitory factor 0.575 1.490 2.571 MIF 
17.39% 
2 2 
12.5 7.88 
P49137 
MAP kinase-activated protein 
kinase 2  -0.500 0.707 -2.278 MAPKAPK2 
8.25% 
3 3 
45.5 8.68 
Q96MG7 
Melanoma-associated antigen 
G1 0.566 1.480 2.527 NDNL2 
25.66% 
7 7 
34.3 9.28 
Q9Y4B5 
Microtubule cross-linking 
factor 1  -0.945 0.520 -4.282 MTCL1 
2.26% 
4 4 
209.4 6.43 
H3BTL1 
Microtubule-associated protein 
1 light chain 3 beta, isoform 
CRA_f 0.628 1.546 2.809 MAP1LC3B 
37.33% 
3 3 
9 9.82 
Q9BYG3 
MKI67 FHA domain-
interacting nucleolar 
phosphoprotein  -0.562 0.678 -2.555 NIFK 
6.83% 
2 2 
34.2 9.88 
Q9BQG0 Myb-binding protein 1A  -0.457 0.729 -2.083 MYBBP1A 35.32% 38 38 148.8 9.28 
Q09666 
Neuroblast differentiation-
associated protein AHNAK  0.704 1.629 3.149 AHNAK 
50.12% 
152 147 
628.7 6.15 
Q59F20 Neuropilin-1 variant -0.443 0.736 -2.021 N/A 15.73% 10 10 99.6 5.94 
O60287 
Nucleolar pre-ribosomal-
associated protein 1  -0.624 0.649 -2.835 URB1 
4.36% 
7 7 
254.2 6.47 
Q8NFH4 Nucleoporin Nup37  -0.525 0.695 -2.389 NUP37 18.71% 5 5 36.7 5.92 
F8W020 
Nucleosome assembly protein 
1-like 1 0.985 1.980 4.419 NAP1L1 
45.41% 
8 7 
24.4 4.51 
A2RUU9 PCM1 protein -0.657 0.634 -2.987 PCM1 3.98% 8 7 209.8 5 
B5MCF9 Pescadillo homolog  -0.670 0.629 -3.044 PES1 14.36% 8 8 66 7.5 
P30086 
Phosphatidylethanolamine-
binding protein 1  0.549 1.463 2.452 PEBP1 
51.87% 
9 9 
21 7.53 
E9PFQ4 
Pleckstrin homology-like 
domain family B member 2  -0.431 0.742 -1.968 PHLDB2 
4.84% 
5 5 
125.4 7.12 
Q9UKK3 
Poly [ADP-ribose] polymerase 
4  -0.770 0.587 -3.493 PARP4 
7.48% 
10 10 
192.5 5.66 
O14737 
Programmed cell death protein 
5 0.565 1.480 2.525 PDCD5 
57.60% 
7 7 
14.3 6.04 
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P60903 Protein S100-A10 1.127 2.184 5.058 S100A10 36.08% 4 4 11.2 7.37 
P31949 Protein S100-A11  1.699 3.248 7.639 S100A11 49.52% 5 5 11.7 7.12 
Q9HBR0 
Putative sodium-coupled 
neutral amino acid transporter 
10 -0.602 0.659 -2.735 SLC38A10 
7.77% 
6 6 
119.7 5.73 
Q6AI38 
Putative uncharacterized protein 
DKFZp762F247 -0.720 0.607 -3.270 DKFZp762F247 
3.62% 
2 2 
75.2 6.25 
Q6IPN0 Reticulon  0.605 1.521 2.703 RTN4 34.69% 8 8 36.9 4.81 
Q8TDN6 
Ribosome biogenesis protein 
BRX1 homolog  -0.597 0.661 -2.716 BRIX1 
22.95% 
6 6 
41.4 9.92 
Q5VXN0 
Ribosome production factor 2 
homolog -0.597 0.661 -2.716 RPF2 
11.21% 
2 2 
24.6 9.55 
P51692 
Signal transducer and activator 
of transcription 5B  0.443 1.359 1.973 STAT5B 
7.24% 
4 4 
89.8 6.05 
Q9BWJ5 Splicing factor 3B subunit 5 0.627 1.544 2.803 SF3B5 30.23% 2 2 10.1 6.35 
Q96SB8 
Structural maintenance of 
chromosomes protein 6  0.604 1.520 2.701 SMC6 
3.67% 
3 3 
126.2 6.99 
Q9BYN0 Sulfiredoxin-1 0.543 1.457 2.423 SRXN1 83.94% 8 8 14.3 8.19 
M0R3F6 
SURP and G-patch domain-
containing protein 2 -0.581 0.669 -2.642 SUGP2 
2.38% 
2 2 
93.8 8.84 
B5BU32 Thymidine kinase  0.489 1.403 2.180 TK1 39.32% 7 7 25.4 8.63 
Q01995 Transgelin  0.517 1.431 2.306 TAGLN 34.33% 6 6 22.6 8.84 
Q96LD4 
Tripartite motif-containing 
protein 47  -0.964 0.513 -4.371 TRIM47 
28.21% 
13 13 
69.5 6.44 
B7Z588 
Tumor necrosis factor receptor 
superfamily member 10B 0.787 1.726 3.526 TNFRSF10B 
16.92% 
3 3 
28.7 5.22 
Q86YV5 
Tyrosine-protein kinase 
SgK223  -0.551 0.683 -2.507 SGK223 
5.90% 
6 6 
149.5 7.2 
Q96GS4 
Uncharacterized protein 
C17orf59  0.938 1.916 4.207 C17orf59 
9.52% 
2 2 
37.2 5.76 
B8ZZQ6 Uncharacterized protein 0.456 1.372 2.034 PTMA 23.36% 4 4 11.8 3.81 
Q12965 Unconventional myosin-Ie -0.636 0.644 -2.890 MYO1E 25.54% 22 21 127 8.92 
A0A0J9YY01 Unconventional myosin-XVB -0.502 0.706 -2.287 MYO15B 1.96% 4 3 333.5 7.72 
P08670 Vimentin  -1.072 0.476 -4.858 VIM 64.38% 32 29 53.6 5.12 
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G3V2D5 
Zinc finger protein 36, C3H1 
type-like 1 1.005 2.008 4.510 ZFP36L1 
10.23% 
2 2 
19.5 9.66 
I6L9C8 Zinc finger protein 428  0.871 1.829 3.905 ZNF428 14.89% 2 2 20.5 4.17 
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APPENDIX B-Differentially expressed proteins at 24 hours helichrysetin treatment 
Accession Description 
log2 
protein 
ratio 
protein 
ratio 
Z score Gene name Coverage 
Matched 
peptides 
Unique 
peptides 
MW 
[kDa] 
calc. pI 
P15428 
15-hydroxyprostaglandin 
dehydrogenase [NAD(+)]  -0.629 0.647 -2.184 HPGD 
23.68% 
9 9 
29 5.86 
A0A024RBQ5 2'-5'-oligoadenylate synthetase 3 -0.900 0.536 -3.115 OAS3 6.99% 6 5 121.1 8.35 
C9JYQ9 60S ribosomal protein L22-like 1  -1.076 0.475 -3.720 RPL22L1 22.31% 3 3 14.5 9.38 
P11021 78 kDa glucose-regulated protein  0.599 1.515 2.044 HSPA5 52.45% 34 31 72.3 5.16 
Q8TDD1 ATP-dependent RNA helicase DDX54  -0.570 0.674 -1.981 DDX54 21.68% 7 6 98.5 10.02 
Q9NR09 
Baculoviral IAP repeat-containing 
protein 6  -0.670 0.629 -2.324 BIRC6 
2.00% 
5 5 
529.9 6.05 
O95817 
BAG family molecular chaperone 
regulator 3  0.722 1.649 2.467 BAG3 
41.22% 
15 15 
61.6 6.95 
Q6PJG6 BRCA1-associated ATM activator 1  -0.993 0.503 -3.436 BRAT1 10.84% 4 4 88.1 5.27 
B4DDF4 Calponin-2  -0.615 0.653 -2.134 CNN2 45.97% 10 9 32.6 6.98 
A5PLM9 Cathepsin L1  0.943 1.922 3.228 CTSL1 17.12% 4 4 37.5 5.45 
E9PNW4 CD59 glycoprotein  0.664 1.585 2.269 CD59 29.63% 3 3 12 5.74 
Q9Y696 Chloride intracellular channel protein 4 0.640 1.558 2.185 CLIC4 36.76% 12 12 28.8 5.59 
O75153 
Clustered mitochondria protein 
homolog  -0.605 0.658 -2.100 CLUH 
30.14% 
30 2 
146.6 6.13 
P38432 Coilin  -0.707 0.613 -2.452 COIL 6.77% 3 3 62.6 9.07 
Q6PUV4 Complexin-2 -0.948 0.519 -3.280 CPLX2 43.28% 3 3 15.4 5.08 
Q00534 Cyclin-dependent kinase 6  -0.621 0.650 -2.157 CDK6 13.80% 5 4 36.9 6.46 
P38936 Cyclin-dependent kinase inhibitor 1  0.781 1.718 2.671 CDKN1A 19.51% 3 3 18.1 8.37 
O43175 D-3-phosphoglycerate dehydrogenase 0.736 1.666 2.516 PHGDH 32.27% 12 12 56.6 6.71 
K7ESP4 
Dephospho-CoA kinase domain-
containing protein  0.821 1.767 2.809 DCAKD 
30.14% 
4 4 
24.2 9.67 
P15924 Desmoplakin  -0.932 0.524 -3.228 DSP 3.97% 11 10 331.6 6.81 
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P26358 DNA (cytosine-5)-methyltransferase 1 -0.700 0.616 -2.428 DNMT1 13.92% 17 17 183 7.75 
Q2NKX8 
DNA excision repair protein ERCC-6-
like -0.616 0.653 -2.138 ERCC6L 
4.08% 
6 6 
141 5.31 
P28340 DNA polymerase delta catalytic subunit  -0.656 0.635 -2.277 POLD1 23.31% 15 14 123.6 7.03 
A0A087WU64 DNA polymerase  -0.807 0.572 -2.797 POLA1 2.19% 4 4 165.7 5.85 
A8K7A0 DNA primase large subunit -0.773 0.585 -2.681 N/A 14.15% 4 4 58.8 7.91 
B2RBY4 DNA primase  -0.775 0.585 -2.685 N/A 12.14% 5 5 49.9 8.38 
P25685 DnaJ homolog subfamily B member 1 0.610 1.527 2.084 DNAJB1 45.88% 16 15 38 8.63 
Q96T88 E3 ubiquitin-protein ligase UHRF1  -0.886 0.541 -3.069 UHRF1 8.32% 3 3 89.8 7.56 
P07099 Epoxide hydrolase 1 0.700 1.625 2.393 EPHX1 52.09% 17 17 52.9 7.25 
D3DVF0 F11 receptor, isoform CRA_a 0.575 1.490 1.962 F11R 31.42% 3 3 32.2 7.12 
Q9BXW9 Fanconi anemia group D2 protein -1.419 0.374 -4.903 FANCD2 5.51% 2 2 164 5.88 
O60427 Fatty acid desaturase 1  -0.765 0.589 -2.651 FADS1 16.44% 2 2 51.9 8.87 
O95864 Fatty acid desaturase 2  -1.876 0.273 -6.475 FADS2 14.19% 5 5 52.2 8.82 
P02792 Ferritin light chain  1.274 2.419 4.369 FTL 48.57% 7 7 20 5.78 
E9PG40 
Gamma-secretase C-terminal fragment 
59 0.886 1.848 3.033 APP 
17.79% 
10 9 
80.8 4.82 
A0A0G2JPW5 Gamma-tubulin complex component 5  -0.737 0.600 -2.555 TUBGCP5 3.22% 2 2 118.3 5.94 
Q9Y5Q9 
General transcription factor 3C 
polypeptide 3  -0.902 0.535 -3.124 GTF3C3 
10.50% 
6 6 
101.2 5.07 
Q5T7U1 
General transcription factor 3C 
polypeptide 5 -0.725 0.605 -2.514 GTF3C5 
10.07% 
3 3 
52.3 6.37 
Q86Y56 HEAT repeat-containing protein 2  -0.701 0.615 -2.432 HEATR2 21.05% 14 14 93.5 6.42 
Q6AI08 HEAT repeat-containing protein 6 -1.094 0.469 -3.784 HEATR6 4.57% 5 5 128.7 7.03 
P08107;P0DMV8 Heat shock 70 kDa protein 1A/1B 1.541 2.910 5.288 HSPA1A 63.65% 34 22 70 5.66 
Q92598 Heat shock protein 105 kDa  0.613 1.530 2.093 HSPH1 55.24% 45 41 96.8 5.39 
P09601 Heme oxygenase 1  2.761 6.781 9.490 HMOX1 47.22% 10 10 32.8 8.25 
O15431 High affinity copper uptake protein 1 0.627 1.544 2.140 SLC31A1 15.79% 2 2 21.1 7.42 
P16403 Histone H1.2  -0.793 0.577 -2.749 HIST1H1C 36.15% 9 4 21.4 10.93 
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Q96KK5 Histone H2A type 1-H  0.628 1.546 2.145 HIST1H2AH 27.34% 3 2 13.9 10.89 
P62805 Histone H4 0.837 1.786 2.863 HIST1H4A 58.25% 5 5 11.4 11.36 
B7Z3K3 Inositol-3-phosphate synthase 1  -0.569 0.674 -1.977 ISYNA1 9.27% 3 3 38.8 5.4 
Q59EZ3 
Insulin-like growth factor 2 receptor 
variant 0.581 1.496 1.982 N/A 
13.92% 
28 28 
265.9 5.83 
Q92667-2 Isoform 2 of A-kinase anchor protein 1 -0.651 0.637 -2.258 AKAP1 10.79% 3 3 62.9 4.84 
P08243-2 
Isoform 2 of Asparagine synthetase 
[glutamine-hydrolyzing] 1.161 2.236 3.978 ASNS 
35.00% 
17 17 
62.1 7.06 
Q12789-3 
Isoform 2 of General transcription 
factor 3C polypeptide 1  -0.733 0.602 -2.542 GTF3C1 
9.31% 
11 10 
236.1 7.52 
Q4G148-2 
Isoform 2 of Glucoside 
xylosyltransferase 1  1.070 2.099 3.665 GXYLT1 
5.87% 
3 3 
46.8 8.95 
Q9NR48-2 
Isoform 2 of Histone-lysine N-
methyltransferase ASH1L  1.596 3.024 5.478 ASH1L 
0.78% 
2 2 
332 9.39 
Q5TA45-2 
Isoform 2 of Integrator complex subunit 
11 -0.570 0.674 -1.981 CPSF3L 
7.62% 
3 3 
56 8.32 
Q6KB66-2 
Isoform 2 of Keratin, type II 
cytoskeletal 80  -1.053 0.482 -3.643 KRT80 
7.35% 
5 4 
47.2 5.3 
P10619-2 
Isoform 2 of Lysosomal protective 
protein  0.595 1.510 2.030 CTSA 
10.58% 
6 6 
52.5 6.98 
O15091-2 
Isoform 2 of Mitochondrial 
ribonuclease P protein 3 -0.575 0.672 -1.996 KIAA0391 
17.99% 
6 6 
65.4 8.5 
Q9NVV4-2 Isoform 2 of Poly(A) RNA polymerase -0.915 0.531 -3.166 MTPAP 6.74% 5 4 78.8 8.28 
Q9UNS1-2 Isoform 2 of Protein timeless homolog  -1.436 0.370 -4.963 TIMELESS 4.81% 4 4 138.4 5.38 
Q9NUQ6-2 Isoform 2 of SPATS2-like protein  -0.619 0.651 -2.150 SPATS2L 18.00% 6 6 54.1 9.63 
Q5UIP0-2 
Isoform 2 of Telomere-associated 
protein RIF1  -0.643 0.641 -2.230 RIF1 
11.45% 
10 10 
271.5 5.41 
O43294-2 
Isoform 2 of Transforming growth 
factor beta-1-induced transcript 1 
protein -0.665 0.631 -2.308 TGFB1I1 
4.95% 
3 3 
47.9 7.58 
P45880-2 
Isoform 2 of Voltage-dependent anion-
selective channel protein 2 -0.800 0.575 -2.771 VDAC2 
50.18% 
12 12 
30.4 7.2 
P16278-3 Isoform 3 of Beta-galactosidase  0.589 1.504 2.010 GLB1 23.65% 9 9 72.7 6.25 
Q3B7T1-4 
Isoform 3 of Erythroid differentiation-
related factor 1  -0.605 0.658 -2.100 EDRF1 
4.27% 
2 2 
66 5.38 
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Q6YHU6-3 
Isoform 3 of Thyroid adenoma-
associated protein  -1.243 0.423 -4.297 THADA 
3.69% 
3 3 
211 6.1 
P10909-4 Isoform 4 of Clusterin  0.673 1.595 2.300 CLU 21.15% 4 4 48.8 6.71 
P53355-4 
Isoform 4 of Death-associated protein 
kinase 1  -0.989 0.504 -3.421 DAPK1 
3.59% 
7 6 
152.4 7.17 
Q9BQ52-4 
Isoform 4 of Zinc phosphodiesterase 
ELAC protein 2  -0.601 0.660 -2.085 ELAC2 
29.90% 
17 17 
87.5 7.97 
Q9BV36-5 Isoform 5 of Melanophilin  -0.596 0.662 -2.070 MLPH 8.10% 3 2 50.7 6.19 
Q9NRZ9-6 
Isoform 6 of Lymphoid-specific 
helicase -1.119 0.461 -3.869 HELLS 
10.73% 
8 8 
81.6 7.83 
P52948-6 
Isoform 6 of Nuclear pore complex 
protein Nup98-Nup96  -0.608 0.656 -2.112 NUP98 
11.30% 
13 13 
186.2 6.29 
Q5GLZ8-6 
Isoform 6 of Probable E3 ubiquitin-
protein ligase HERC4  -0.813 0.569 -2.818 HERC4 
11.24% 
10 10 
106.6 6.47 
Q5VYS8-6 
Isoform 6 of Terminal 
uridylyltransferase 7  0.688 1.611 2.351 ZCCHC6 
4.21% 
5 5 
166.9 6.87 
Q93062-4 
Isoform D of RNA-binding protein with 
multiple splicing  -0.824 0.565 -2.853 RBPMS 
41.96% 
2 2 
15.8 8.38 
O43493-2 
Isoform TGN46 of Trans-Golgi 
network integral membrane protein 2  0.783 1.721 2.679 TGOLN2 
19.68% 
6 6 
45.9 5.63 
A0A087X106 Keratin, type II cuticular Hb1  -2.318 0.201 -7.999 KRT81 26.86% 12 12 53.1 5.47 
P42166 
Lamina-associated polypeptide 2, 
isoform alpha -0.731 0.603 -2.534 TMPO 
53.31% 
15 8 
75.4 7.66 
P20700 Lamin-B1  -0.890 0.540 -3.083 LMNB1 39.25% 14 12 66.4 5.16 
Q03252 Lamin-B2  -0.741 0.599 -2.567 LMNB2 14.17% 5 3 67.6 5.35 
E9PP40 
Leucine-rich repeat-containing protein 
14  -1.117 0.461 -3.864 LRRC14 
10.30% 
3 3 
33.5 8.31 
B4DJ65 Major prion protein 0.822 1.768 2.812 N/A 17.47% 3 3 25.3 9 
Q96MG7 Melanoma-associated antigen G1  0.636 1.554 2.171 NDNL2 25.00% 7 7 34.3 9.28 
Q9Y4B5 Microtubule cross-linking factor 1  -1.020 0.493 -3.530 MTCL1 4.41% 4 4 209.4 6.43 
H3BTL1 
Microtubule-associated protein 1 light 
chain 3 beta, isoform CRA_f  0.933 1.909 3.194 MAP1LC3B 
37.33% 
3 3 
9 9.82 
Q9NU22 Midasin -0.625 0.649 -2.169 MDN1 3.43% 17 17 632.4 5.68 
E7ENQ1 
Mitogen-activated protein kinase kinase 
kinase kinase 4  -0.589 0.665 -2.044 MAP4K4 
2.69% 
3 3 
132.1 7.53 
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Q8IVT2 
Mitotic interactor and substrate of 
PLK1  -0.607 0.657 -2.108 MISP 
14.87% 
6 6 
75.3 6.83 
H7C173 Mitotic-spindle organizing protein 2B  -0.644 0.640 -2.234 MZT2B 16.39% 3 3 12.5 10.46 
Q59EG3 MutL protein homolog 1 variant -0.626 0.648 -2.173 N/A 9.78% 6 6 62.3 6.54 
Q9BQG0 Myb-binding protein 1A  -0.648 0.638 -2.250 MYBBP1A 35.77% 38 38 148.8 9.28 
P16435 NADPH--cytochrome P450 reductase 0.692 1.615 2.363 POR 43.72% 33 33 76.6 5.58 
O60287 
Nucleolar pre-ribosomal-associated 
protein 1 -0.705 0.614 -2.444 URB1 
8.28% 
7 7 
254.2 6.47 
A0A024QZW7 Nucleoporin 153kDa, isoform CRA_a -0.718 0.608 -2.489 NUP153 11.25% 6 5 153.9 8.73 
Q8NFH4 Nucleoporin Nup37 -0.842 0.558 -2.915 NUP37 11.04% 5 5 36.7 5.92 
Q96EE3 Nucleoporin SEH1  -0.678 0.625 -2.352 SEH1L 22.50% 4 4 39.6 8.09 
Q56VL3 OCIA domain-containing protein 2 -0.711 0.611 -2.465 OCIAD2 25.97% 4 4 16.9 9.03 
Q9BTU6 
Phosphatidylinositol 4-kinase type 2-
alpha  0.683 1.606 2.334 PI4K2A 
26.93% 
14 14 
54 8.29 
Q9Y617 Phosphoserine aminotransferase 0.617 1.534 2.108 PSAT1 53.51% 16 16 40.4 7.66 
Q14914 Prostaglandin reductase 1  0.641 1.560 2.190 PTGR1 53.82% 14 14 35.8 8.29 
Q9H694 Protein bicaudal C homolog 1 -0.847 0.556 -2.933 BICC1 4.32% 3 3 104.8 8.54 
Q86VR2 Protein FAM134C  0.589 1.504 2.010 FAM134C 14.81% 4 4 51.4 4.97 
P31949 Protein S100-A11 0.692 1.616 2.367 S100A11 34.29% 5 5 11.7 7.12 
B3KW34 Protein YIPF 0.586 1.502 2.001 N/A 8.17% 2 2 28 4.36 
Q5JQ44 
Putative uncharacterized protein 
DKFZp547A0616  0.620 1.537 2.116 DKFZp547A0616 
53.04% 
8 5 
20.3 4.81 
Q6AI38 
Putative uncharacterized protein 
DKFZp762F247  -0.634 0.645 -2.199 DKFZp762F247 
4.68% 
2 2 
75.2 6.25 
F2Z2E2 
Ras GTPase-activating-like protein 
IQGAP3 -0.643 0.641 -2.230 IQGAP3 
7.37% 
14 10 
179.4 7.66 
P31350 
Ribonucleoside-diphosphate reductase 
subunit M2  -0.976 0.509 -3.377 RRM2 
21.59% 
10 9 
44.8 5.38 
Q5VXN0 Ribosome production factor 2 homolog -0.868 0.548 -3.005 RPF2 15.42% 2 2 24.6 9.55 
Q9NZJ4 Sacsin -0.886 0.541 -3.069 SACS 0.57% 2 2 520.8 7.05 
B2RWP0 
Signal-induced proliferation-associated 
1 like 3  -0.654 0.636 -2.269 SIPA1L3 
1.52% 
4 4 
194.5 8.32 
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Q9BYN0 Sulfiredoxin-1  1.131 2.190 3.876 SRXN1 47.45% 8 8 14.3 8.19 
M0R3F6 
SURP and G-patch domain-containing 
protein 2  -0.576 0.671 -1.999 SUGP2 
10.11% 
2 2 
93.8 8.84 
B4DKR0 Syntaxin 5A, isoform CRA_c  0.642 1.561 2.195 STX5 28.96% 6 6 29.2 7.15 
Q68CZ2 Tensin-3  -1.047 0.484 -3.622 TNS3 14.05% 17 17 155.2 6.81 
Q9H0U9 Testis-specific Y-encoded-like protein 1  0.733 1.663 2.507 TSPYL1 13.27% 6 6 49.2 5.45 
Q96LD4 Tripartite motif-containing protein 47  -1.315 0.402 -4.544 TRIM47 15.52% 13 13 69.5 6.44 
Q13641 Trophoblast glycoprotein  0.601 1.517 2.051 TPBG 14.52% 5 5 46 6.83 
Q5TCU3 Tropomyosin beta chain  -0.590 0.665 -2.048 TPM2 47.18% 19 2 32.8 4.68 
Q03169 
Tumor necrosis factor alpha-induced 
protein 2 -0.673 0.627 -2.336 TNFAIP2 
22.02% 
15 15 
72.6 6.46 
B7Z588 
Tumor necrosis factor receptor 
superfamily member 10B 0.976 1.967 3.343 TNFRSF10B 
31.15% 
3 3 
28.7 5.22 
Q86YV5 Tyrosine-protein kinase SgK223 -0.617 0.652 -2.142 SGK223 5.48% 6 6 149.5 7.2 
Q9BXV9 Uncharacterized protein C14orf142  1.071 2.101 3.669 C14orf142 41.00% 2 2 10.9 4.27 
Q12965 Unconventional myosin-Ie  -0.797 0.576 -2.762 MYO1E 17.33% 22 21 127 8.92 
A0A0J9YY01 Unconventional myosin-XVB  -0.881 0.543 -3.051 MYO15B 3.07% 4 3 333.5 7.72 
P08670 Vimentin  -0.909 0.533 -3.148 VIM 61.59% 32 29 53.6 5.12 
P21796 
Voltage-dependent anion-selective 
channel protein 1  -0.802 0.574 -2.779 VDAC1 
54.42% 
12 11 
30.8 8.54 
Q9Y277 
Voltage-dependent anion-selective 
channel protein 3 -1.026 0.491 -3.551 VDAC3 
36.04% 
10 9 
30.6 8.66 
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APPENDIX C-Differentially expressed protein at 48 hours helichrysetin treatment 
Accession Description 
log2 
protein 
ratio 
protein 
ratio 
Z score Gene name Coverage 
Matched 
peptides 
Unique 
peptides 
MW 
[kDa] 
calc. pI 
A0A024RBQ5 2'-5'-oligoadenylate synthetase 3 -1.231 0.426 -3.557 OAS3 5.98% 7 6 121.1 8.35 
B1AK13 
3-hydroxymethyl-3-methylglutaryl-
Coenzyme A lyase 
(Hydroxymethylglutaricaciduria) 1.049 2.069 2.943 HMGCL 
30.67% 
5 5 
31.7 7.61 
C9JYQ9 60S ribosomal protein L22-like 1 -1.315 0.402 -3.795 RPL22L1 35.54% 3 2 14.5 9.38 
Q6NUM9 All-trans-retinol 13,14-reductase  0.877 1.836 2.452 RETSAT 32.62% 16 16 66.8 8.28 
Q06203 Amidophosphoribosyltransferase  -0.699 0.616 -2.040 PPAT 10.44% 6 6 57.4 6.76 
Q9BRQ8 Apoptosis-inducing factor 2  0.744 1.675 2.073 AIFM2 37.00% 7 7 40.5 9.11 
Q9UH62 
Armadillo repeat-containing X-linked 
protein 3  0.834 1.783 2.330 ARMCX3 
8.44% 
3 3 
42.5 8.37 
J3QR41 Aurora kinase B -0.981 0.507 -2.845 AURKB 26.16% 2 2 20 8.92 
B4DDF4 Calponin-2 -0.683 0.623 -1.993 CNN2 40.94% 12 10 32.6 6.98 
O15438 
Canalicular multispecific organic anion 
transporter 2  0.743 1.674 2.071 ABCC3 
19.52% 
24 23 
169.2 7.2 
O75976 Carboxypeptidase D  0.879 1.839 2.459 CPD 12.54% 25 25 152.8 6.05 
P07339 Cathepsin D  1.077 2.110 3.024 CTSD 52.18% 14 14 44.5 6.54 
A5PLM9 Cathepsin L1  1.148 2.216 3.225 CTSL1 13.51% 5 5 37.5 5.45 
F8VNT9 CD63 antigen 0.886 1.848 2.479 CD63 13.53% 2 2 14.3 7.59 
Q6PUV4 Complexin-2  -1.484 0.358 -4.278 CPLX2 36.57% 2 2 15.4 5.08 
Q00534 Cyclin-dependent kinase 6 -1.094 0.469 -3.166 CDK6 18.71% 4 3 36.9 6.46 
P38936 Cyclin-dependent kinase inhibitor 1 1.156 2.229 3.249 CDKN1A 24.39% 2 2 18.1 8.37 
E7EVJ5 
Cytoplasmic FMR1-interacting protein 
2  0.797 1.738 2.225 CYFIP2 
18.91% 
13 2 
142.5 7.17 
O43175 D-3-phosphoglycerate dehydrogenase  1.015 2.021 2.846 PHGDH 32.65% 13 13 56.6 6.71 
K7ESP4 
Dephospho-CoA kinase domain-
containing protein 0.910 1.880 2.548 DCAKD 
21.05% 
5 5 
24.2 9.67 
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P15924 Desmoplakin -0.825 0.565 -2.399 DSP 4.25% 9 8 331.6 6.81 
P36957 
Dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydrogenase complex 0.711 1.637 1.979 DLST 
38.85% 
14 14 
48.7 8.95 
Q9UHL4 Dipeptidyl peptidase 2  0.728 1.657 2.029 DPP7 12.60% 7 7 54.3 6.32 
P26358 DNA (cytosine-5)-methyltransferase 1  -0.913 0.531 -2.651 DNMT1 12.93% 20 20 183 7.75 
Q2NKX8 
DNA excision repair protein ERCC-6-
like  -0.905 0.534 -2.628 ERCC6L 
6.48% 
3 3 
141 5.31 
A0A087WU64 DNA polymerase -1.224 0.428 -3.538 POLA1 3.35% 3 3 165.7 5.85 
A8K7A0 DNA primase large subunit  -1.063 0.479 -3.079 N/A 9.23% 6 6 58.8 7.91 
B2RBY4 DNA primase -1.044 0.485 -3.023 N/A 14.76% 6 5 49.9 8.38 
Q96T88 E3 ubiquitin-protein ligase UHRF1  -0.704 0.614 -2.053 UHRF1 4.04% 5 5 89.8 7.56 
D6RBS5 ELMO domain-containing protein 2 0.795 1.735 2.218 ELMOD2 23.95% 4 4 20.1 9.09 
P30040 
Endoplasmic reticulum resident protein 
29 0.733 1.663 2.044 ERP29 
46.36% 
11 11 
29 7.31 
Q9UNN8 Endothelial protein C receptor  0.788 1.727 2.199 PROCR 20.59% 4 4 26.7 7.18 
J3KMY5 Epididymal secretory protein E1  0.811 1.754 2.264 NPC2 48.65% 6 6 16.2 7.65 
P07099 Epoxide hydrolase 1  1.569 2.966 4.425 EPHX1 50.33% 24 24 52.9 7.25 
Q99808 Equilibrative nucleoside transporter 1  -0.723 0.606 -2.107 SLC29A1 5.48% 4 4 50.2 8.29 
E7EQG2 Eukaryotic initiation factor 4A-II  1.069 2.099 3.002 EIF4A2 45.03% 14 3 41.3 5.64 
Q9BXW9 Fanconi anemia group D2 protein -1.315 0.402 -3.795 FANCD2 1.52% 7 7 164 5.88 
P02792 Ferritin light chain 1.025 2.036 2.876 FTL 44.00% 7 7 20 5.78 
A0A024R8Q1 
Glucosidase, alpha acid (Pompe 
disease, glycogen storage disease type 
II) 0.729 1.658 2.033 GAA 
16.28% 
14 14 
105.3 6 
P35052 Glypican-1 0.818 1.763 2.285 GPC1 26.16% 8 8 61.6 7.3 
Q2NLC8 GSTK1 protein 0.748 1.680 2.086 GSTK1 63.58% 9 9 19.4 8.69 
P63096 
Guanine nucleotide-binding protein 
G(i) subunit alpha-1 0.712 1.639 1.984 GNAI1 
39.27% 
8 4 
40.3 5.97 
Q86Y56 HEAT repeat-containing protein 2  -0.684 0.623 -1.997 HEATR2 20.82% 16 16 93.5 6.42 
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P08107;P0DMV8 Heat shock 70 kDa protein 1A/1B 1.264 2.401 3.556 HSPA1A 64.59% 34 29 70 5.66 
P09601 Heme oxygenase 1  1.720 3.295 4.858 HMOX1 46.53% 12 12 32.8 8.25 
P16403 Histone H1.2 -0.851 0.555 -2.473 HIST1H1C 38.97% 10 3 21.4 10.93 
P16401 Histone H1.5 -0.712 0.611 -2.077 HIST1H1B 21.24% 7 5 22.6 10.92 
Q96KK5 Histone H2A type 1-H 1.252 2.382 3.523 HIST1H2AH 27.34% 3 2 13.9 10.89 
A8K9J7 Histone H2B  1.060 2.085 2.974 N/A 40.48% 6 6 14 10.32 
P62805 Histone H4  2.015 4.042 5.697 HIST1H4A 45.63% 7 7 11.4 11.36 
Q70UQ0 
Inhibitor of nuclear factor kappa-B 
kinase-interacting protein  0.775 1.712 2.163 IKBIP 
35.43% 
11 7 
39.3 9.17 
Q59EZ3 
Insulin-like growth factor 2 receptor 
variant  0.720 1.647 2.005 N/A 
14.46% 
27 27 
265.9 5.83 
P43353-2 
Isoform 2 of Aldehyde dehydrogenase 
family 3 member B1  0.961 1.947 2.692 ALDH3B1 
17.40% 
6 5 
47.7 7.81 
P08243-2 
Isoform 2 of Asparagine synthetase 
[glutamine-hydrolyzing] 0.795 1.735 2.218 ASNS 
42.78% 
17 17 
62.1 7.06 
P14635-2 
Isoform 2 of G2/mitotic-specific 
cyclin-B1  -0.753 0.594 -2.193 CCNB1 
11.62% 
4 4 
44.1 7.37 
Q4G148-2 
Isoform 2 of Glucoside 
xylosyltransferase 1  0.890 1.853 2.490 GXYLT1 
8.80% 
3 3 
46.8 8.95 
Q6KB66-2 
Isoform 2 of Keratin, type II 
cytoskeletal 80 -1.308 0.404 -3.775 KRT80 
13.98% 
5 4 
47.2 5.3 
P10619-2 
Isoform 2 of Lysosomal protective 
protein  0.982 1.976 2.753 CTSA 
12.31% 
6 6 
52.5 6.98 
Q9BTE3-2 
Isoform 2 of Mini-chromosome 
maintenance complex-binding protein -0.807 0.572 -2.348 MCMBP 
20.78% 
10 10 
72.7 5.78 
Q969Z3-2 
Isoform 2 of Mitochondrial amidoxime 
reducing component 2  0.796 1.737 2.223 MARC2 
11.28% 
3 3 
29.1 9.79 
Q8NFW8-2 
Isoform 2 of N-acylneuraminate 
cytidylyltransferase 0.794 1.734 2.217 CMAS 
13.69% 
3 3 
29.5 8.57 
Q6T4R5-2 
Isoform 2 of Nance-Horan syndrome 
protein  -1.094 0.469 -3.166 NHS 
13.69% 
2 2 
176.6 6.79 
P57740-2 
Isoform 2 of Nuclear pore complex 
protein Nup107  -0.767 0.588 -2.235 NUP107 
1.60% 
13 13 
103.1 5.33 
Q9UKX7-2 
Isoform 2 of Nuclear pore complex 
protein Nup50 -0.904 0.535 -2.624 NUP50 
19.32% 
7 7 
46.8 8.27 
Q9NVV4-2 Isoform 2 of Poly(A) RNA polymerase -0.672 0.628 -1.964 MTPAP 8.43% 5 4 78.8 8.28 
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Q9H8V3-2 Isoform 2 of Protein ECT2  -0.913 0.531 -2.651 ECT2 9.30% 6 6 99.9 7.61 
Q9UNS1-2 Isoform 2 of Protein timeless homolog  -1.170 0.445 -3.382 TIMELESS 4.14% 4 4 138.4 5.38 
Q5UIP0-2 
Isoform 2 of Telomere-associated 
protein RIF1  -0.925 0.527 -2.686 RIF1 
5.97% 
10 10 
271.5 5.41 
O43294-2 
Isoform 2 of Transforming growth 
factor beta-1-induced transcript 1 
protein  -0.980 0.507 -2.841 TGFB1I1 
5.86% 
3 3 
47.9 7.58 
Q9UM00-2 
Isoform 2 of Transmembrane and 
coiled-coil domain-containing protein 1 0.742 1.673 2.068 TMCO1 
18.93% 
3 3 
18.8 9.61 
O14773-2 Isoform 2 of Tripeptidyl-peptidase 1  1.157 2.230 3.252 TPP1 17.19% 3 3 34.4 6.09 
Q71U36-2 Isoform 2 of Tubulin alpha-1A chain 0.965 1.953 2.705 TUBA1A 72.60% 21 1 46.3 5.08 
Q9UIG0-2 
Isoform 2 of Tyrosine-protein kinase 
BAZ1B -0.704 0.614 -2.053 BAZ1B 
14.54% 
16 16 
170.3 8.48 
P45880-2 
Isoform 2 of Voltage-dependent anion-
selective channel protein 2 -1.432 0.371 -4.131 VDAC2 
57.60% 
12 12 
30.4 7.2 
P16278-3 Isoform 3 of Beta-galactosidase  0.973 1.963 2.726 GLB1 17.31% 9 9 72.7 6.25 
Q5JU85-3 
Isoform 3 of IQ motif and SEC7 
domain-containing protein 2 0.739 1.669 2.060 IQSEC2 
5.06% 
4 3 
105 7.24 
Q6YHU6-3 
Isoform 3 of Thyroid adenoma-
associated protein -0.739 0.599 -2.155 THADA 
2.39% 
3 3 
211 6.1 
O00291-4 
Isoform 4 of Huntingtin-interacting 
protein 1  -0.735 0.601 -2.141 HIP1 
7.64% 
7 7 
113 5.2 
Q9H6X2-5 Isoform 5 of Anthrax toxin receptor 1  -0.801 0.574 -2.330 ANTXR1 12.88% 5 5 59.2 7.23 
Q9NRZ9-6 
Isoform 6 of Lymphoid-specific 
helicase  -1.171 0.444 -3.387 HELLS 
11.86% 
8 8 
81.6 7.83 
P52948-6 
Isoform 6 of Nuclear pore complex 
protein Nup98-Nup96 -0.743 0.598 -2.165 NUP98 
9.22% 
13 13 
186.2 6.29 
P15529-7 
Isoform L of Membrane cofactor 
protein 0.736 1.665 2.050 CD46 
10.14% 
3 3 
39.8 5.8 
Q13907 
Isopentenyl-diphosphate Delta-
isomerase 1  0.920 1.892 2.575 IDI1 
32.16% 
6 6 
26.3 6.34 
P08779 Keratin, type I cytoskeletal 16  -0.766 0.588 -2.231 KRT16 21.99% 13 2 51.2 5.05 
A0A087X106 Keratin, type II cuticular Hb1  -1.279 0.412 -3.694 KRT81 25.21% 12 12 53.1 5.47 
B7Z6Q6 Kinesin-like protein KIF2C  -0.694 0.618 -2.027 KIF2C 7.31% 4 3 76.9 8.06 
P50748 Kinetochore-associated protein 1  -0.695 0.618 -2.030 KNTC1 2.58% 4 4 250.6 5.97 
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P42166 
Lamina-associated polypeptide 2, 
isoform alpha -0.797 0.576 -2.320 TMPO 
30.55% 
15 8 
75.4 7.66 
P20700 Lamin-B1 -1.293 0.408 -3.734 LMNB1 24.06% 14 12 66.4 5.16 
Q03252 Lamin-B2  -1.039 0.487 -3.011 LMNB2 7.83% 5 3 67.6 5.35 
Q96KB5 
Lymphokine-activated killer T-cell-
originated protein kinase -0.743 0.598 -2.165 PBK 
22.36% 
6 6 
36.1 5.12 
Q14108 Lysosome membrane protein 2  0.732 1.661 2.040 SCARB2 23.22% 10 10 54.3 5.14 
B4E2S7 
Lysosome-associated membrane 
glycoprotein 2  0.799 1.740 2.231 LAMP2 
10.47% 
4 4 
39.8 5.67 
P14174 Macrophage migration inhibitory factor 0.916 1.888 2.566 MIF 17.39% 2 2 12.5 7.88 
Q9UM22 
Mammalian ependymin-related protein 
1  0.775 1.712 2.163 EPDR1 
17.86% 
5 5 
25.4 6.6 
P02795 Metallothionein-2  -0.771 0.586 -2.245 MT2A 32.79% 2 2 6 7.83 
Q9Y4B5 Microtubule cross-linking factor 1 -0.762 0.590 -2.221 MTCL1 2.26% 4 4 209.4 6.43 
Q9NU22 Midasin -0.676 0.626 -1.974 MDN1 4.59% 17 17 632.4 5.68 
O96008 
Mitochondrial import receptor subunit 
TOM40 homolog  -0.772 0.586 -2.249 TOMM40 
42.66% 
11 11 
37.9 7.25 
P33527 
Multidrug resistance-associated protein 
1 0.718 1.645 1.999 ABCC1 
27.69% 
33 31 
171.5 7.11 
P35580 Myosin-10 -0.782 0.582 -2.277 MYH10 33.96% 55 35 228.9 5.54 
Q9UHQ9 NADH-cytochrome b5 reductase 1  0.847 1.799 2.368 CYB5R1 36.07% 8 8 34.1 9.38 
P16435 NADPH--cytochrome P450 reductase  1.053 2.075 2.954 POR 56.87% 33 33 76.6 5.58 
Q92621 Nuclear pore complex protein Nup205  -0.778 0.583 -2.266 NUP205 21.92% 34 34 227.8 6.19 
J3KMX1 Nuclear pore complex protein Nup88  -0.706 0.613 -2.060 NUP88 16.09% 8 8 78.8 5.81 
A0A024QZW7 Nucleoporin  -0.948 0.519 -2.749 NUP153 3.80% 6 5 153.9 8.73 
Q8NFH4 Nucleoporin Nup37  -0.884 0.542 -2.566 NUP37 18.71% 5 5 36.7 5.92 
Q96EE3 Nucleoporin SEH1  -0.748 0.596 -2.179 SEH1L 14.17% 4 4 39.6 8.09 
Q9H173 Nucleotide exchange factor SIL1  1.098 2.141 3.083 SIL1 9.54% 4 4 52.1 5.36 
Q56VL3 OCIA domain-containing protein 2  -0.671 0.628 -1.961 OCIAD2 25.97% 4 4 16.9 9.03 
Q9BTU6 
Phosphatidylinositol 4-kinase type 2-
alpha 0.763 1.697 2.127 PI4K2A 
34.66% 
14 14 
54 8.29 
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Q9BTY2 Plasma alpha-L-fucosidase  0.782 1.720 2.182 FUCA2 3.21% 2 2 54 6.25 
P07602 Prosaposin  1.206 2.308 3.392 PSAP 33.02% 16 16 58.1 5.17 
O14684 Prostaglandin E synthase  0.742 1.672 2.067 PTGES 18.42% 3 3 17.1 9.5 
Q14914 Prostaglandin reductase 1  1.127 2.185 3.167 PTGR1 63.22% 14 14 35.8 8.29 
Q9H694 Protein bicaudal C homolog 1  -0.704 0.614 -2.053 BICC1 3.18% 3 3 104.8 8.54 
Q8WYJ5 Protein kinase C inhibitor-2  0.954 1.938 2.673 N/A 65.63% 6 6 13.9 7.05 
P31949 Protein S100-A11  0.763 1.697 2.127 S100A11 49.52% 5 5 11.7 7.12 
Q9H900 Protein zwilch homolog -0.970 0.511 -2.813 ZWILCH 11.34% 4 4 67.2 6.27 
Q8NHP8 Putative phospholipase B-like 2  0.736 1.665 2.050 PLBD2 9.34% 5 5 65.4 6.8 
F2Z2E2 
Ras GTPase-activating-like protein 
IQGAP3 -0.946 0.519 -2.745 IQGAP3 
9.70% 
14 10 
179.4 7.66 
Q12913 
Receptor-type tyrosine-protein 
phosphatase eta  0.782 1.720 2.182 PTPRJ 
1.35% 
2 2 
145.9 5.58 
Q9HB40 
Retinoid-inducible serine 
carboxypeptidase  0.951 1.933 2.664 SCPEP1 
15.93% 
5 5 
50.8 5.81 
Q9H477 Ribokinase  0.714 1.640 1.988 RBKS 7.76% 3 3 34.1 5.05 
P31350 
Ribonucleoside-diphosphate reductase 
subunit M2  -1.044 0.485 -3.023 RRM2 
28.79% 
10 9 
44.8 5.38 
Q5VXN0 Ribosome production factor 2 homolog -0.796 0.576 -2.316 RPF2 11.21% 2 2 24.6 9.55 
Q9NZJ4 Sacsin -0.955 0.516 -2.769 SACS 0.72% 2 2 520.8 7.05 
I3L0X5 Sperm-associated antigen 7  -0.771 0.586 -2.245 SPAG7 13.64% 2 2 20.1 5.74 
Q13586 Stromal interaction molecule 1  0.743 1.674 2.071 STIM1 21.17% 11 11 77.4 6.67 
Q9BYN0 Sulfiredoxin-1  1.022 2.031 2.867 SRXN1 83.94% 8 8 14.3 8.19 
Q9NXH8 Torsin-4A  -0.956 0.516 -2.773 TOR4A 22.70% 8 8 46.9 9.94 
A0A0C4DFM1 
Transmembrane 9 superfamily member 
4 0.877 1.836 2.452 TM9SF4 
15.36% 
8 8 
72.5 6.65 
Q9NUM4 Transmembrane protein 106B  0.998 1.997 2.798 TMEM106B 21.17% 5 5 31.1 6.99 
Q96LD4 Tripartite motif-containing protein 47  -0.977 0.508 -2.833 TRIM47 28.21% 13 13 69.5 6.44 
Q5TCU3 Tropomyosin beta chain  -0.767 0.588 -2.235 TPM2 53.52% 19 2 32.8 4.68 
O75208 Ubiquinone biosynthesis protein COQ9 0.730 1.659 2.035 COQ9 20.75% 5 5 35.5 5.94 
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Q12965 Unconventional myosin-Ie -0.802 0.574 -2.334 MYO1E 25.54% 22 21 127 8.92 
A0A0J9YY01 Unconventional myosin-XVB -0.872 0.547 -2.532 MYO15B 1.96% 4 3 333.5 7.72 
P08670 Vimentin  -0.853 0.554 -2.480 VIM 64.38% 32 29 53.6 5.12 
P21796 
Voltage-dependent anion-selective 
channel protein 1  -1.444 0.368 -4.164 VDAC1 
60.42% 
12 11 
30.8 8.54 
Q9Y277 
Voltage-dependent anion-selective 
channel protein 3 -1.715 0.305 -4.938 VDAC3 
45.58% 
10 9 
30.6 8.66 
 
 
 
 
